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DEVELOPMENT OF A PREVENTIVE IDV infection has been associated with BRDC , one of the 
INFLUENZA D VIRUS VACCINE most devastating diseases of the cattle population . An effi 
cacious vaccine is needed to prevent infection and stop 
STATEMENT REGARDING FEDERALLY potential cross - species transmission . In this study , a DNA SPONSORED RESEARCH OR DEVELOPMENT 5 vaccine encoding the consensus HEF of two lineages of IDV 
None . ( D / OK and D / 660 ) ( SEQ ID NO . 1 ) was designed and its efficacy was tested in a guinea pig model . The results 
BACKGROUND showed that the consensus DNA vaccine ( SEQ ID NO . 2 ) 
elicited high - titer neutralizing antibodies and achieved ster 
Influenza D virus ( IDV ) has recently been classified as a ilizing protection against two lineage - representative IDV 
new genus within the Orthomyxoviridae family and is intra - nasal infections . It is believed that this is the first study 
distinct from influenza A , B , and C viruses ( IAV , IBV , ICV , showing a DNA vaccine - expressing consensus HEF is effi respectively ) . IDV infects economically important domestic cacious in preventing different lineages of influenza D virus livestock , including swine and cattle , and has been associ infections . ated with a respiratory disease / influenza - like illness . Fur- 15 In one aspect of the disclosure , a DNA vaccine or immu thermore , IDV seroprevalence in humans was estimated to 
be approximately 1.3 % in the general population and over nogenic composition is provided . Preferably , the vaccine or 
90 % in individuals working with cattle . These initial studies immunogenic composition has a nucleotide sequence having 
suggest that IDV may have the potential to infect humans , at least 85 % , more preferably 90 % , still more preferably 91 , 
although its pathogenicity to humans remains unknown . 20 92 , 93 , 94 , 95 , 96 , 97 , 98 , 99 , 99.5 , or 100 % sequence 
IDV has a broad host range . IDV was initially isolated homology with SEQ ID NO.2 and / or encodes an amino acid 
from clinically ill pigs expressing influenza - like symptoms sequence having at least 85 % , more preferably 90 % , still 
in 2011. However , subsequently epidemiological data sug nore preferably 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , 99 , 99.5 , or gest cattle are the primary reservoir . In addition to swine and 
cattle , IDV infections have been reported in goat , sheep , 100 % sequence homology with SEQ ID NO . 1 . 
equine , buffalo , and camel . IDV has also been shown to In another aspect of the disclosure , a protein - based vac 
infect ferrets and guinea pigs in experimental settings . IDV cine or immunogenic composition is provided . Preferably , 
infections are widely distributed across many countries in the vaccine or immunogenic composition is encoded by a 
the American , Asian , European , and African continents . nucleotide sequence having at least 85 % , more preferably 
With a broad host range and high environmental stability , 90 % , still more preferably 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , 99 , 
IDV has the potential to further gain virulence , or even infect 99.5 , or 100 % sequence homology with SEQ ID NO . 2 
humans . and / or has an amino acid sequence having at least 85 % , 
Two lineages of IDVs were found to be co - circulating in more preferably 90 % , still more preferably 91 , 92 , 93 , 94 , 
the United States . Recently , a potential third lineage of IDV 95 , 96 , 97 , 98 , 99 , 99.5 , or 100 % sequence homology with was identified in Japan . IDV , like other Influenza viruses , is a single - strand , negative - sense segmented and enveloped 35 SEQ ID NO . 1 . 
RNA virus . Both IAV and IBV have eight genomic segments In another aspect of the disclosure , a method of reducing 
and two surface glycoproteins of hemagglutinin ( HA ) and the incidence of or severity of clinical signs of IDV infection 
neuraminidase ( NA ) . IDV like ICV has only seven genomic in an individual animal is provided . In general , the method 
segments and one spike hemagglutinin - esterase - fusion comprises the step of administering an immunogenic com 
( HEF ) protein . The HEF combines the functions of HA and 40 position or vaccine to an animal in need thereof wherein the 
NA for receptor binding , receptor destruction , and mem- immunogenic composition has a nucleotide sequence having 
brane fusion activity . While the overall structure of IDV at least 85 % , more preferably 90 % , still more preferably 91 , 
HEF is similar to ICV , IDV HEF has an open receptor 92 , 93 , 94 , 95 , 96 , 97 , 98 , 99 , 99.5 , or 100 % sequence 
binding cavity to accommodate diverse extended glycan homology with SEQ ID NO . 2 and / or encodes an amino acid moieties , which may be one of the reasons for its broad host 45 sequence having at least 85 % , more preferably 90 % , still range . more preferably 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , 99 , 99.5 , or IDV causes only mild or no obvious clinical symptoms in 
infected animals . However , it is thought to be a facilitating 100 % sequence homology with SEQ ID NO . 1. In some 
factor for the development of bovine respiratory disease forms , the nucleotide sequence is combined with a carrier . In 
complex ( BRDC ) , which is one of the most commonly some forms , the nucleotide sequence is combined with an diagnosed causes of morbidity and mortality within the 50 adjuvant . In some forms , the nucleotide sequence is con 
cattle industry . An efficacious preventative vaccine is needed tained within a vector . In some forms , the vector is a 
to protect economically important domestic animals and plasmid . In some forms , the vector is the pJW4303 vector . 
limit potential cross - species transmission to humans . In another aspect of the disclosure , a method of reducing 
What is needed is an immunogenic composition that the incidence of or severity of clinical signs of IDV infection 
provides protection against IDV infection and / or reduces at 55 in a group or herd of animals is provided . In general , the 
least one of the following : the incidence of IDV infection , method comprises the step of administering an immuno 
the severity of clinical signs caused by or associated with genic composition or vaccine to a group of animals in need 
IDV infection , the incidence of clinical signs caused by or thereof wherein the immunogenic composition has a nucleo 
associated with IDV infection , and the susceptibility to IDV tide sequence having at least 85 % , more preferably 90 % , 
infection . What is further needed is an immunogenic com- 60 still more preferably 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , 99 , 99.5 , 
position that reduces the possibility of cross - species trans- or 100 % sequence homology with SEQ ID NO . 2 and / or 
mission of IDV to other animals including humans . encodes an amino acid sequence having at least 85 % , more 
preferably 90 % , still more preferably 91 , 92 , 93 , 94 , 95 , 96 , 
SUMMARY OF THE DISCLOSURE 97 , 98 , 99 , 99.5 , or 100 % sequence homology with SEQ ID 
65 NO . 1. In some forms , the nucleotide sequence is combined 
The present disclosure overcomes the problems inherent with a carrier . In some forms , the nucleotide sequence is 
in the art including those described above . combined with an adjuvant . In some forms , the nucleotide 
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sequence is contained within a vector . In some forms , the with SEQ ID NO . 1. In some forms , the amino acid sequence 
vector is a plasmid . In some forms , the vector is the is combined with a carrier . In some forms , the amino acid 
PJW4303 vector . sequence is combined with an adjuvant . In some forms , the 
In another aspect of the disclosure , a method of reducing nucleotide sequence used to express the amino acid 
the incidence of or severity of clinical signs of IDV infection 5 sequence is contained within a vector . In some forms , the 
in an individual animal is provided . In general , the method vector is a plasmid . In some forms , the vector is the 
comprises the step of administering an immunogenic com- pJW4303 vector .
position or vaccine to an animal in need thereof wherein the In another aspect of the disclosure , the immunogenic 
immunogenic composition is encoded by a nucleotide composition or vaccine as disclosed herein is combined with 
sequence having at least 85 % , more preferably 90 % , still 10 or administered concurrently with an antigen that reduces 
more preferably 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , 99 , 99.5 , or the incidence of or severity of clinical signs of another 
100 % sequence homology with SEQ ID NO . 2 and / or has an pathogen . In some forms , the other pathogen is a virus . In 
amino acid sequence having at least 85 % , more preferably some forms , the other pathogen is a bacteria . In some forms ,
90 % , still more preferably 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , 99 , the immunogenic composition of the present disclosure is 
99.5 , or 100 % sequence homology with SEQ ID NO . 1. In 15 combined with the other antigen such that they are in the 
some forms , the amino acid sequence is combined with a same container or administration vehicle . In some forms , the 
carrier . In some forms , the amino acid sequence is combined other antigen is administered concurrently or within 5 min 
with an adjuvant . utes , 1 hour , 3 hours , 5 hours , 10 hours , 18 hours , 24 hours , 
In another aspect of the disclosure , a method of reducing 36 hours , 48 hours , 72 hours , or 96 hours of the adminis 
the incidence of or severity of clinical signs of IDV infection 20 tration of the immunogenic composition or vaccine of the 
in a group or herd of animals is provided . In general , the present disclosure . In some forms , the pathogen is selected 
method comprises the step of administering an immuno- from the group consisting of at least one swine pathogen , 
genic composition or vaccine to a group of animals in need preferably one described below and / or at least one cattle 
thereof wherein the immunogenic composition is encoded pathogen , preferably selected from the group consisting of 
by a nucleotide sequence having at least 85 % , more pref- 25 Bovine Viral Diarrhea Virus , Bovine Herpesvirus , Pasteur 
erably 90 % , still more preferably 91 , 92 , 93 , 94 , 95 , 96 , 97 , ella , Mannheimia , Bluetongue Virus , Bovine Parvovirus , 
98 , 99 , 99.5 , or 100 % sequence homology with SEQ ID NO . Bovine Parainfluenza Virus , Bovine Respiratory Syncytial 
2 and / or has an amino acid sequence having at least 85 % , Virus , and Fusobacterium . 
more preferably 90 % , still more preferably 91 , 92 , 93 , 94 , In another aspect of the disclosure a method of producing 
95 , 96 , 97 , 98 , 99 , 99.5 , or 100 % sequence homology with 30 and / or recovering recombinant HEF IDV protein is pro 
SEQ ID NO . 1. In some forms , the amino acid sequence is vided . In general , the method includes the steps of 1 ) 
combined with a carrier . In some forms , the amino acid infecting a number of susceptible cells in culture with a 
sequence is combined with an adjuvant . recombinant viral vector encoding a HEF IDV protein , 2 ) 
In another aspect of the disclosure , a method of making an expressing HEF IDV protein by the recombinant viral vec 
immunogenic composition or vaccine that provides protec- 35 tor , 3 ) recovering the HEF IDV protein , and , 4 ) separating 
tion by reducing the incidence of or severity of clinical signs cell debris from the expressed HEF IDV protein via a 
of IDV infection in an individual animal or group of animals separation step . 
is provided . The method generally comprises the steps of In another aspect of the present disclosure , the inclusion 
inserting a desired nucleotide sequence into a vector and of an inactivation step is preferred in order to inactivate the 
administering the vector to an animal or animals in need 40 viral vector prior to recovery of HEF IDV protein that will 
thereof . Preferably , the nucleotide sequence has at least be used in an immunogenic or immunological composition 
85 % , more preferably 90 % , still more preferably 91 , 92 , 93 , such as a vaccine . Such a step can be performed as step 5 ) 
94 , 95 , 96 , 97 , 98 , 99 , 99.5 , or 100 % sequence homology in addition to steps 1-4 described above . 
with SEQ ID NO . 2 and / or encodes an amino acid sequence In some forms , this inactivation is done either just before 
having at least 85 % , more preferably 90 % , still more pref- 45 or just after the filtration or separation step . Any conven 
erably 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , 99 , 99.5 , or 100 % tional inactivation method can be used for purposes of the 
sequence homology with SEQ ID NO . 1. In some forms , the present disclosure . Thus , inactivation can be performed by 
vector containing the nucleotide sequence is combined with chemical and / or physical treatments . One representative 
a carrier . In some forms , the vector containing the nucleotide inactivation method includes the addition of cyclized binary 
sequence is combined with an adjuvant . In some forms , the 50 ethylenimine ( BEI ) . 
vector is a plasmid . In some forms , the vector is the Optionally , the method described above may also include 
pJW4303 vector . Preferably , the inserted nucleotide a neutralization step after step 5 ) . For example , if the 
sequence is expressed in vivo after being administered to the inactivation agent is BEI , addition of sodium thiosulfate to 
animal or group of animals . an equivalent amount is preferred . Preferably , the sodium 
In another aspect of the disclosure , a method of making an 55 thiosulfate is added in equivalent amount as compared to the 
immunogenic composition or vaccine is provided . The BEI added for inactivation . 
method generally includes the step of recovering an An “ immunogenic or immunological composition ” refers 
expressed protein or constructing a recombinant protein and to a composition of matter that comprises at least one 
using that protein as the immunogenic composition or antigen which elicits an immunological response in the host 
vaccine . In some forms , the protein is expressed by a 60 of a cellular and / or antibody - mediated immune response to 
nucleotide sequence having at least 85 % , more preferably the composition or vaccine of interest . Usually , an “ immu 
90 % , still more preferably 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , 99 , nological response ” includes but is not limited to one or 
99.5 , or 100 % sequence homology with SEQ ID NO . 2. In more of the following effects : the production or activation of 
some forms , the expressed protein or constructed recombi- antibodies , B cells , helper T cells , suppressor T cells , and / or 
nant protein has an amino acid sequence having at least 65 cytotoxic T cells and / or yd T cells , directed specifically to an 
85 % , more preferably 90 % , still more preferably 91 , 92 , 93 , antigen or antigens included in the composition or vaccine 
94 , 95 , 96 , 97 , 98 , 99 , 99.5 , or 100 % sequence homology of interest . Preferably , the host will display either a thera 
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peutic or protective immunological response such that resis- binant viral vector . In preferred forms and as described 
tance to new infection will be enhanced and / or the clinical above , a neutralization step , step 8 ) , will be performed after 
severity of the disease reduced . Such protection will be step 7 ) . Of course , prior to step 1 ) the HEF IDV DNA can 
demonstrated by either a reduction in the severity or preva- be amplified in vitro , preferably with flanking sequences of 
lence of , up to and including a lack of symptoms normally 5 the HEF IDV DNA , as described above . 
displayed by an infected host , a quicker recovery time and / or In another aspect of the present disclosure , a method for 
a lowered viral titer in the infected host . preparing a composition , preferably an immunogenic com 
In preferred forms and especially in forms that will use the position , such as a vaccine , for invoking an immune 
recombinant HEF IDV protein in an immunogenic compo- response against HEF IDV is provided . Generally , this 
sition such as a vaccine , each lot or just selected lots of 10 method includes the steps of transfecting a construct into a 
harvested HEF IDV protein can be tested for inactivation . virus , wherein the construct comprises 1 ) recombinant DNA 
Thus a further aspect of the present disclosure relates to an from HEF IDV , 2 ) infecting cells in growth media with the 
inactivation test for determining the effectiveness of the transfected virus , 3 ) causing the virus to express the recom 
inactivation of the recombination viral vector , comprising binant protein from HEF IDV , 4 ) recovering the expressed 
the steps : 1 ) contacting at least a portion of the culture fluid 15 recombinant protein , 5 ) and preparing the composition by 
containing the recombinant viral vector with an inactivating combining the recovered protein with a suitable adjuvant 
agent , 2 ) adding a neutralization agent to neutralize the and / or other pharmaceutically acceptable carrier . In some 
inactivation agent , and 3 ) determining the residual infectiv- preferred forms , the composition also includes at least a 
ity . portion of the viral vector expressing said HEF IDV protein , 
In preferred forms the recombinant viral vector containing 20 and / or a portion of the cell culture supernate 
HEF IDV DNA and expressing HEF IDV protein used to “ Adjuvants ” as used herein , can include aluminum 
infect the cells is generated by transfecting a transfer vector hydroxide and aluminum phosphate , saponins e.g. , Quil A , 
that has had a HEF IDV gene cloned therein into a viral QS - 21 ( Cambridge Biotech Inc. , Cambridge , Mass . ) , GPI 
vector . Preferably , only the portion of the transfer vector that 0100 ( Galenica Pharmaceuticals , Inc. , Birmingham , Ala . ) , 
contains the desired HEF IDV DNA is transfected into the 25 water - in - oil emulsion , oil - in - water emulsion , water - in - oil 
viral vector . in - water emulsion . The emulsion can be based in particular 
The term “ transfected into a viral vector ” means , and is on light liquid paraffin oil ( European Pharmacopea type ) ; 
used as a synonym for “ introducing ” or “ cloning ” a heter- isoprenoid oil such as squalane or squalene oil resulting 
ologous DNA into a viral vector , such as for example into a from theoligomerization of alkenes , in particular of 
baculovirus vector . A “ transfer vector ” means a DNA mol- 30 isobutene or decene ; esters of acids or of alcohols containing 
ecule , that includes at least one origin of replication , the a linear alkyl group , more particularly plant oils , ethyl 
heterologous gene , in the present case of HEF IDV , DNA oleate , propylene glycol di- ( caprylate / caprate ) , glyceryl tri 
sequences which allow the cloning of said heterologous ( caprylate / caprate ) or propylene glycol di ate ; esters of 
gene into the viral vector will be included . Preferably the branched fatty acids or alcohols , in particular isostearic acid 
sequences which allow cloning of the heterologous gene into 35 esters . The oil is used in combination with emulsifiers to 
the viral vector are flanking the heterologous gene . Even form the emulsion . The emulsifiers are preferably nonionic 
more preferably , those flanking sequences are at least surfactants , in particular esters of sorbitan , of mannide ( e.g. 
homologous in parts with sequences of the viral vector . The anhydromannitol oleate ) , of glycol , of polyglycerol , of pro 
sequence homology then allows recombination of both pylene glycol and of oleic , isostearic , ricinoleic or hydrox 
molecules , the viral vector , and the transfer vector to gen- 40 ystearic acid , which are optionally ethoxylated , and poly 
erate a recombinant viral vector containing the heterologous oxypropylene - polyoxyethylene copolymer blocks , in 
gene . particular the Pluronic products , especially L121 . See 
In another aspect of the disclosure , a method of making Hunter et al . , The Theory and Practical Application of 
the HEF IDV protein will begin with the isolation of HEF Adjuvants ( Ed . Stewart - Tull , D. E. S. ) . John Wiley and 
IDV DNA . Any HEF IDV gene can be used for purposes of 45 Sons , NY , pp 51-94 ( 1995 ) and Todd et al . , Vaccine 15 : 564 
the present disclosure . The HEF IDV DNA is preferably 570 ( 1997 ) . 
amplified using PCR methods . The resulting DNA is then For example , it is possible to use the SPT emulsion 
cloned into the transfer vector . described on page 147 of “ Vaccine Design , The Subunit and 
Thus , in one aspect of the present disclosure , a method for Adjuvant Approach ” edited by M. Powell and M. Newman , 
constructing a recombinant viral vector containing HEF IDV 50 Plenum Press , 1995 , and the emulsion MF59 described on 
DNA is provided . This method generally comprises the steps page 183 of this same book . 
of : 1 ) cloning at least one recombinant HEF IDV gene into A further instance of an adjuvant is a compound chosen 
a transfer vector ; from the polymers of acrylic or methacrylic acid and the 
and 2 ) transfecting the portion of the transfer vector copolymers of maleic anhydride and alkenyl derivative . 
containing the recombinant HEF IDV gene into a viral 55 Advantageous adjuvant compounds are the polymers of 
vector , to generate the recombinant viral vector . acrylic or methacrylic acid which are cross - linked , espe 
A further aspect of the present disclosure relates to a cially with polyalkenyl ethers of sugars or polyalcohols . 
method for preparing a composition comprising HEF IDV These compounds are known by the term carbomer 
protein , and inactivated viral vector . This method generally ( Phameuropa Vol . 8 , No. 2 , June 1996 ) . Persons skilled in 
comprises the steps of : 1 ) cloning the amplified HEF IDV 60 the art can also refer to U.S. Pat . No. 2,909,462 which 
DNA into a transfer vector ; 2 ) transfecting the portion of the describes such acrylic polymers cross - linked with a poly 
transfer vector containing the recombinant HEF IDV DNA hydroxylated compound having at least 3 hydroxyl groups , 
into a virus ; 3 ) infecting cells in media with the transfected preferably not more than 8 , the hydrogen atoms of at least 
viral vector ; 4 ) causing the transfected viral vector to three hydroxyls being replaced by unsaturated aliphatic 
express the recombinant protein from the HEF IDV DNA ; 5 ) 65 radicals having at least 2 carbon atoms . The preferred 
separating cells from the supernate ; 6 ) recovering the radicals are those containing from 2 to 4 carbon atoms , e.g. 
expressed HEF IDV protein ; and 7 ) inactivating the recom- vinyls , allyls and other ethylenically unsaturated groups . 
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The unsaturated radicals may themselves contain other 80 % ( v / v ) , still more preferably about 70 % ( v / v ) . Optionally , 
substituents , such as methyl . The products sold under the this method can also include the addition of a protectant . A 
name Carbopol ; ( BF Goodrich , Ohio , USA ) are particularly protectant as used herein , refers to an anti - microbiological 
appropriate . They are cross - linked with an allyl sucrose or active agent , such as for example Gentamycin , Merthiolate , 
with allyl pentaerythritol . Among then , there may be men- 5 and the like . In particular adding a protectant is most 
tioned Carbopol 974P , 934P and 971P . Among the copoly- preferred for the preparation of a multi - dose composition . 
mers of maleic anhydride and alkenyl derivative , the copo- Those anti - microbiological active agents are added in con 
lymers EMA ( Monsanto ) which are copolymers of maleic centrations effective to prevent the composition of interest 
anhydride and ethylene . The dissolution of these polymers in from any microbiological contamination or for inhibition of 
water leads to an acid solution that will be neutralized , 10 any microbiological growth within the composition of inter 
preferably to physiological pH , in order to give the adjuvant est . 
solution into which the immunogenic , immunological or The methods and compositions of the present disclosure 
vaccine composition itself will be incorporated . can also comprise the addition of any stabilizing agent , such 
Further suitable adjuvants include , but are not limited to , as for example saccharides , trehalose , mannitol , saccharose 
the RIBI adjuvant system ( Ribi Inc. ) , Block co - polymer 15 and the like , to increase and / or maintain product shelf - life 
( CytRx , Atlanta , Ga . ) , SAF - M ( Chiron , Emeryville , Calif . ) , and / or to enhance stability . 
monophosphoryl lipid A , Avridine lipid - amine adjuvant , In another aspect of the present disclosure , products 
heat - labile enterotoxin from E. coli ( recombinant or other- resulting from the methods as described above are provided . 
wise ) , cholera toxin , IMS 1314 or muramyl dipeptide among In particular , the present disclosure relates to a composition 
many others . 20 of matter comprising recombinantly expressed HEF IDV 
Preferably , the adjuvant is added in an amount of about protein . In some preferred forms , this composition of matter 
100 ug to about 10 mg per dose . Even more preferably , the also comprises an agent suitable for the inactivation of viral 
adjuvant is added in an amount of about 100 ug to about 10 vectors . Such products are useful as immunogenic compo 
mg per dose . Even more preferably , the adjuvant is added in sitions that induce an immune response and , more prefer 
an amount of about 500 ug to about 5 mg per dose . Even 25 ably , confers protective immunity against the clinical signs 
more preferably , the adjuvant is added in an amount of about of HEF IDV infection . The composition generally comprises 
750 ug to about 2.5 mg per dose . Most preferably , the the polypeptide , or a fragment thereof , expressed by HEF as 
adjuvant is added in an amount of about 1 mg per dose . the antigenic component of the composition . Of course , it is 
In another aspect of the present disclosure , a method for understood that the HEF IDV polypeptide used in an immu 
preparing an immunogenic composition , such as a vaccine , 30 nogenic composition in accordance with the present disclo 
for invoking an immune response against HEF IDV com- sure can be derived in any fashion including isolation and 
prises the steps of 1 ) expressing and recovering HEF IDV purification , standard protein synthesis , and recombinant 
protein , and 2 ) admixing the recovered protein with a methodology 
suitable adjuvant . Preferably , the expressing step 1 ) includes Clinical signs of IDV infection are generally mild respi 
the steps as described for the preparation and recovery of 35 ratory symptoms , but also include contribution to bovine 
HEF IDV protein . Another optional step for this method respiratory disease and bovine respiratory disease complex . 
includes cloning the amplified HEF IDV DNA into a first Additionally , viral load , antibody titers , apoptosis of cells , 
vector , excising the DNA from this first vector , and using programmed cell death , and RNA load in tissues and cells 
this excised HEF IDV DNA for cloning into the transfer ( including epithelial and non - epithelial cells ) from the as 
vector . Preferably , the recovery step of this method also 40 trachea , lung , nasal septum , nasal turbinates , bronchioles , 
includes the step of separating the media from the cells and and alveoli are also clinical signs of infection . 
cell debris . This can be done in any conventional manner , “ Sequence Identity ” as it is known in the art refers to a 
with one preferred manner comprising filtering the cells , cell relationship between two or more polypeptide sequences or 
debris , and growth media through a filter having pores two or more polynucleotide sequences , namely a reference 
ranging in size from about 0.45 uM to about 1.0 uM . Finally , 45 sequence and a given sequence to be compared with the 
for this aspect , it is preferred to include a virus inactivation reference sequence . Sequence identity is determined by 
step prior to combining the recovered recombinant HEF comparing the given sequence to the reference sequence 
IDV protein in a composition . When an inactivation step is after the sequences have been optimally aligned to produce 
included , it is also preferred to include a neutralization step , the highest degree of sequence similarity , as determined by 
as described above . 50 the match between strings of such sequences . Upon such 
Additionally , the composition can include one or more alignment , sequence identity is ascertained on a position 
pharmaceutical - acceptable or veterinary - acceptable carriers . by - position basis , e.g. , the sequences are “ identical ” at a 
As used herein , “ a pharmaceutical - acceptable carrier " or particular position if at that position , the nucleotides or 
" veterinary - acceptable carrier " includes any and all sol- amino acid residues are identical . The total number of such 
vents , dispersion media , coatings , stabilizing agents , 55 position identities is then divided by the total number of 
diluents , preservatives , antibacterial and antifungal agents , nucleotides or residues in the reference sequence to give % 
isotonic agents , adsorption delaying agents , and the like . In sequence identity . Sequence identity can be readily calcu 
one preferred form , the composition provided herewith , lated by known methods , including but not limited to , those 
contains HEF IDV protein recovered from in vitro cultured described in Computational Molecular Biology , Lesk , A. N. , 
cells , wherein said cells were infected with a recombinant 60 ed . , Oxford University Press , New York ( 1988 ) , Biocom 
viral vector containing HEF IDV DNA and expressing HEF puting : Informatics and Genome Projects , Smith , D. W. , ed . , 
IDV protein , and wherein the cell culture was treated to Academic Press , New York ( 1993 ) ; Computer Analysis of 
inactivate the viral vector , and an equivalent concentration Sequence Data , Part I , Griffin , A. M. , and Griffin , H. G. , eds . , 
of a neutralization agent was added , and wherein both an Humana Press , New Jersey ( 1994 ) ; Sequence Analysis in 
adjuvant and physiological saline are also added . When 65 Molecular Biology , von Heinge , G. , Academic Press ( 1987 ) ; 
included , the amount of physiological saline is preferably Sequence Analysis Primer , Gribskov , M. and Devereux , J. , 
about 50 to about 90 % ( v / v ) , more preferably about 60 to eds . , M. Stockton Press , New York ( 1991 ) ; and Carillo , H. , 
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and Lipman , D. , SIAM J. Applied Math . , 48 : 1073 ( 1988 ) , substitutions . However , conservative substitutions are not 
the teachings of which are incorporated herein by reference . included as a match when determining sequence identity . 
Preferred methods to determine the sequence identity are “ Sequence homology ” , as used herein , refers to a method 
designed to give the largest match between the sequences of determining the relatedness of two sequences . To deter 
tested . Methods to determine sequence identity are codified 5 mine sequence homology , two or more sequences are opti 
in publicly available computer programs which determine mally aligned , and gaps are introduced if necessary . How 
sequence identity between given sequences . Examples of ever , in contrast to " sequence identity ” , conservative amino 
such programs include , but are not limited to , the GCG acid substitutions are counted as a match when determining 
program package ( Devereux , J. , et al . , Nucleic Acids sequence homology . In other words , to obtain a polypeptide 
Research , 12 ( 1 ) : 387 ( 1984 ) ) , BLASTP , BLASTN and 10 or polynucleotide having 95 % sequence homology with a 
FASTA ( Altschul , S. F. et al . , J. Molec . Biol . , 215 : 403-410 reference sequence , 85 % , preferably 90 % , even more pref 
( 1990 ) . The BLASTX program is publicly available from erably 95 % of the amino acid residues or nucleotides in the 
NCBI and other sources ( BLAST Manual , Altschul , S. et al . , reference sequence must match or comprise a conservative 
NCVI NLM NIH Bethesda , Md . 20894 , Altschul , S. F. et al . , substitution with another amino acid or nucleotide , or a 
J. Molec . Biol . , 215 : 403-410 ( 1990 ) , the teachings of which 15 number of amino acids or nucleotides up to 15 % , preferably 
are incorporated herein by reference ) . These programs opti- up to 10 % , even more preferably up to 5 % of the total amino 
mally align sequences using default gap weights in order to acid residues or nucleotides , not including conservative 
produce the highest level of sequence identity between the substitutions , in the reference sequence may be inserted into 
given and reference sequences . As an illustration , by a the reference sequence . Preferably the homologous 
polynucleotide having a nucleotide sequence having at least , 20 sequence comprises at least a stretch of 50 , even more 
for example , 85 % , preferably 90 % , even more preferably preferably 100 , even more preferably 250 , even more pref 
95 % “ sequence identity ” to a reference nucleotide sequence , erably 500 nucleotides . 
it is intended that the nucleotide sequence of the given A “ conservative substitution ” refers to the substitution of 
polynucleotide is identical to the reference sequence except an amino acid residue or nucleotide with another amino acid 
that the given polynucleotide sequence may include up to 25 residue or nucleotide having similar characteristics or prop 
15 , preferably up to 10 , even more preferably up to 5 point erties including size , hydrophobicity , etc. , such that the 
mutations per each 100 nucleotides of the reference nucleo- overall functionality does not change significantly . 
tide sequence . In other words , in a polynucleotide having a Isolated ” means altered " by the hand of man ” from its 
nucleotide sequence having at least 85 % , preferably 90 % , natural state , i.e. , if it occurs in nature , it has been changed 
even more preferably 95 % identity relative to the reference 30 or removed from its original environment , or both . For 
nucleotide sequence , up to 15 % , preferably 10 % , even more example , a polynucleotide or polypeptide naturally present 
preferably 5 % of the nucleotides in the reference sequence in a living organism is not “ isolated , ” but the same poly 
may be deleted or substituted with another nucle nucleotide or polypeptide separated from the coexisting 
number of nucleotides up to 15 % , preferably 10 % , even materials of its natural state is “ isolated ” , as the term is 
more preferably 5 % of the total nucleotides in the reference 35 employed herein . 
sequence may be inserted into the reference sequence . These According to a further aspect , HEF IDV protein is pro 
mutations of the reference sequence may occur at the 5 ' or vided in the immunological composition at an antigen 
3 ' terminal positions of the reference nucleotide sequence or inclusion level effective for inducing the desired immune 
anywhere between those terminal positions , interspersed response , namely reducing the incidence of or lessening the 
either individually among nucleotides in the reference 40 severity of clinical signs resulting from IDV infection . 
sequence or in one or more contiguous groups within the Preferably , the HEF IDV protein inclusion level is at least 
reference sequence . Analogously , by a polypeptide having a 0.2 ug antigen / ml of the final immunogenic composition 
given amino acid sequence having at least , for example , ( ug / ml ) , more preferably from about 0.2 to about 400 ug / ml .
85 % , preferably 90 % , even more preferably 95 % sequence The polypeptide is incorporated into a composition that 
identity to a reference amino acid sequence , it is intended 45 can be administered to an animal susceptible to IDV infec 
that the given amino acid sequence of the polypeptide is tion . In preferred forms , the composition may also include 
identical to the reference sequence except that the given additional components known to those of skill in the art ( see 
polypeptide sequence may include up to 15 , preferably up to also Remington's Pharmaceutical Sciences . ( 1990 ) . 18th ed . 
10 , even more preferably up to 5 amino acid alterations per Mack Publ . , Easton ) . 
each 100 amino acids of the reference amino acid sequence . 50 Those of skill in the art will understand that the compo 
In other words , to obtain a given polypeptide sequence sition herein may incorporate known injectable , physiologi 
having at least 85 % , preferably 90 % , even more preferably cally acceptable , sterile solutions . For preparing a ready - to 
95 % sequence identity with a reference amino acid use solution for parenteral injection or infusion , aqueous 
sequence , up to 15 % , preferably up to 10 % , even more isotonic solutions , such as e.g. saline or corresponding 
preferably up to 5 % of the amino acid residues in the 55 plasma protein solutions are readily available . In addition , 
reference sequence may be deleted or substituted with the immunogenic and vaccine compositions of the present 
another amino acid , or a number of amino acids up to 15 % , disclosure can include diluents , isotonic agents , stabilizers , 
preferably up to 10 % , even more preferably up to 5 % of the or adjuvants . Diluents can include water , saline , dextrose , 
total number of amino acid residues in the reference ethanol , glycerol , and the like . Isotonic agents can include 
sequence may be inserted into the reference sequence . These 60 sodium chloride , dextrose , mannitol , sorbitol , and lactose , 
alterations of the reference sequence may occur at the amino among others . Stabilizers include albumin and alkali salts of 
or the carboxy terminal positions of the reference amino acid ethylendiamintetracetic acid , among others . Suitable adju 
sequence or anywhere between those terminal positions , vants , are those described above . 
interspersed either individually among residues in the ref- According to a further aspect , the immunogenic compo 
erence sequence or in the one or more contiguous groups 65 sition of the present disclosure further comprises a pharma 
within the reference sequence . Preferably , residue positions ceutical acceptable salt , preferably a phosphate salt in physi 
which are not identical differ by conservative amino acid ologically acceptable concentrations . Preferably , the pH of 
or a 
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said immunogenic composition is adjusted to a physiologi- ister the immune stimulant in a suitable dose . The kit may 
cal pH , meaning between about 6.5 and 7.5 . also comprise a second container , including at least one dose 
The immunogenic compositions described herein can of the immune stimulant .
further include one or more other immunomodulatory agents A further aspect of the present disclosure relates to the kit 
such as , e . g . , interleukins , interferons , or other cytokines . 5 as described above , comprising the immunogenic composi 
The immunogenic compositions can also include Gentami- tion of HEF IDV as provided herewith and the instruction 
cin and Merthiolate . In another preferred embodiment , the manual , wherein the instruction manual further includes the 
present disclosure contemplates vaccine compositions com- information to administer the HEF IDV immunogenic com 
prising from about 1 ug / ml to about 60 ug / ml of antibiotics , position together , or around the same time as , with an 
and more preferably less than about 30 ug / ml of antibiotics . 10 immunogenic composition that comprises an additional anti 
It will be found that the immunogenic compositions gen effective for reducing the severity of or incidence of 
comprising recombinant HEF IDV protein as provided here- clinical signs related to another cattle or porcine pathogen . 
with are very effective in reducing the severity of or inci- Preferably , the manual contains the information of when the 
dence of clinical signs associated with IDV infections up to HEF IDV containing composition and the immunogenic 
and including the prevention of such signs . 15 composition that comprises an additional antigen are admin 
Another aspect of the present disclosure relates to a kit . istered . 
Generally the kit includes a container comprising at least A further aspect , relates to the use of any of the compo 
one dose of the immunogenic composition of HEF IDV sitions provided herewith as a medicament , preferably as a 
nucleotide sequence or protein as provided herewith , veterinary medicament , even more preferably as a vaccine . 
wherein one dose comprises at least 100 ug / kg of the animal 20 Moreover , the present disclosure also relates to the use of 
weight of the plasmid containing the HEF IDV nucleotide any of the compositions described herein , for the preparation 
sequence or 2 ug HEF IDV protein . Said container can of a medicament for lessening the severity or incidence of 
comprise from 1 to 250 doses of the immunogenic compo- clinical symptoms associated with IDV infection . Prefer 
sition . In some preferred forms , the container contains 1 , 10 , ably , the medicament is for the prevention of IDV infection 
25 , 50 , 100 , 150 , 200 , or 250 doses of the immunogenic 25 in cattle or swine . 
composition of HEF IDV plasmid or protein . Preferably , A further aspect relates to a method for ( 1 ) the prevention 
each of the containers comprising more than one dose of the of an infection , or re - infection with IDV or ( 2 ) the reduction 
immunogenic composition of HEF IDV plasmid or protein in incidence or severity of or elimination of clinical signs or 
further comprises an anti - microbiological active agent . symptoms caused by IDV in a subject , comprising admin 
Those agents are for example , antibiotics including Gen- 30 istering any of the immunogenic compositions provided 
tamicin and Merthiolate and the like . Thus , one aspect of the herewith to a subject in need thereof . Preferably , the subject 
present disclosure relates to a container that comprises from is a cow or pig . It is understood that the reduction is in 
1 to 250 doses of the immunogenic composition of HEF IDV comparison to a subject that has not received an adminis 
plasmid or protein , wherein one dose comprises at least 100 tration of a composition of the present disclosure . Prefer 
ug / kg of the animal weight of the plasmid containing the 35 ably , one dose or two doses of the immunogenic composi 
HEF IDV nucleotide sequence or 2 ug HEF IDV protein , and tion is / are administered , wherein one dose preferably 
Gentamicin and / or Merthiolate , preferably from about 1 comprises at least about 100 ug / kg of the animal weight of 
ug / ml to about 60 ug / ml of antibiotics , and more preferably the plasmid containing the HEF IDV nucleotide sequence or 
less than about 30 ug / ml . In preferred forms , the kit also 2 ug HEF IDV protein . A further aspect relates to the method 
includes an instruction manual , including the information 40 of treatment as described above , wherein a second applica 
for the administration of at least one dose of the immuno- tion of the immunogenic composition is administered . Pref 
genic composition of HEF IDV plasmid protein into ani- erably , the second administration is done with the same 
mals , preferably cattle or pigs to lessen the incidence and / or immunogenic composition , preferably having the same 
severity of clinical symptoms associated with HEF IDV amount of HEF IDV protein . Preferably , the second admin 
infection . Moreover , according to a further aspect , said 45 istration is done at least 14 days beyond the initial admin 
instruction manual comprises the information of a second or istration , even more preferably at least 4 weeks beyond the 
further administration ( s ) of at least one dose of the immu- initial administration . In preferred forms , the method is 
nogenic composition of HEF IDV plasmid or protein , effective after just a single dose of the immunogenic com 
wherein the second administration or any further adminis- position and does not require a second or subsequent admin 
tration is at least 14 days beyond the initial or any former 50 istration in order to confer the protective benefits upon the 
administration . In some preferred forms , said instruction subject . 
manual also includes the information , to administer an According to a further aspect , the present disclosure 
immune stimulant . Preferably , said immune stimulant shall provides a multivalent combination vaccine which includes 
be given at least twice . Preferably , at least 3 , more preferably an immunological agent effective for reducing the incidence 
at least 5 , and even more preferably at least 7 days are 55 of or lessening the severity of IDV infection , and at least one 
between the first and the second or any further administra- immunological active component against another disease 
tion of the immune stimulant . Preferably , the immune stimu- causing organism in swine or cattle . 
lant is given at least 10 days , preferably 15 , even more In particular the immunological agent effective for reduc 
preferably 20 , and still even more preferably at least 22 days ing the incidence of or lessening the severity of IDV 
beyond the initial administration of the immunogenic com- 60 infection is an IDV antigen . Preferably , said IDV antigen is 
position of HEF IDV plasmid or protein . It is understood that a HEF IDV plasmid or protein as provided herewith , or any 
any immune stimulant known to a person skilled in the art immunogenic composition as described above , that com 
can also be used . “ Immune stimulant ” as used herein , means prises HEF IDV plasmid or protein . 
any agent or composition that can trigger a general immune The terms “ immunogenic protein ” , “ immunogenic poly 
response , preferably without initiating or increasing a spe- 65 peptide ” or “ immunogenic amino acid sequence ” as used 
cific immune response , for example the immune response herein refer to any amino acid sequence which elicits an 
against a specific pathogen . It is further instructed to admin- immune response in a host against a pathogen comprising 
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said immunogenic protein , immunogenic polypeptide or preferred embodiment , the immunological active compo 
immunogenic amino acid sequence . An " immunogenic pro- nent is an attenuated microorganism , including modified live 
tein ” , “ immunogenic polypeptide ” or “ immunogenic amino virus ( MLV ) , a killed - microorganism or at least an immu 
acid sequence " as used herein , includes the full - length nological active part of a microorganism . 
sequence of any proteins , analogs thereof , or immunogenic 5 “ Immunological active part of a microorganism ” as used 
fragments thereof . By “ immunogenic fragment ” is meant a herein means a protein- , sugar- , and or glycoprotein con fragment of a protein which includes one or more epitopes taining fraction of a microorganism that comprises at least 
and thus elicits the immunological response against the one antigen that induces or stimulates the immune response 
relevant pathogen . Such fragments can be identified using in an animal to which said component is administered . any number of epitope mapping techniques , well known in 10 According to a preferred embodiment , said immune the art . See , e.g. , Epitope Mapping Protocols in Methods in 
Molecular Biology , Vol . 66 ( Glenn E. Morris , Ed . , 1996 ) response is directed to said immunological active part of a 
Humana Press , Totowa , New Jersey . For example , linear microorganism or to a microorganism comprising said immunological active part . epitopes may be determined by e.g. , concurrently synthe 
sizing large numbers of peptides on solid supports , the 15 The present disclosure also relates to vaccines comprising 
peptides corresponding to portions of the protein molecule , a nucleotide sequence of HEF IDV , or a homologue or 
and reacting the peptides with antibodies while the peptides fragment thereof , and an acceptable pharmaceutical or vet 
are still attached to the supports . Such techniques are known erinary vehicle . In one embodiment of the disclosure , the 
in the art and described in , e.g. , U.S. Pat . No. 4,708,871 ; nucleotide sequence is selected from , SEQ ID NO . 2 or a 
Geysen et al . ( 1984 ) Proc . Natl . Acad . Sci . USA 81 : 3998- 20 homologue or fragment thereof . In another embodiment of 
4002 ; Geysen et al . ( 1986 ) Molec . Immunol . 23 : 709-715 . the disclosure , the homologue has at least 85 , 90 , 91 , 92 , 93 , 
Similarly , conformational epitopes are readily identified by 94 , 95 , 96 , 97 , 98 , 99 , 99.5 , or 100 % sequence identity to 
determining spatial conformation of amino acids such as by , SEQ ID NO . 2. In yet another embodiment , the vaccine 
e.g. , x - ray crystallography and 2 - dimensional nuclear mag- further comprises an adjuvant . 
netic resonance . See , e.g. , Epitope Mapping Protocols , 25 A further aspect of the present disclosure relates to 
supra . Synthetic antigens are also included within the defi vaccines comprising a vector and an acceptable pharmaceu nition , for example , polyepitopes , flanking epitopes , and tical or veterinary vehicle , the vector comprising a nucleo other recombinant or synthetically derived antigens . See , tide sequence of HEF IDV , preferably SEQ ID NO . 2 , or a e.g. , Bergmann et al . ( 1993 ) Eur . J. Immunol . 23 : 2777-2781 ; homologue or fragment thereof . Bergmann et al . ( 1996 ) , J. Immunol . 157 : 3242-3249 ; Suhr- 30 Additionally , the present disclosure relates to methods of bier , A. ( 1997 ) , Immunol . and Cell Biol . 75 : 402-408 ; Gard immunizing a mammal against IDV comprising administer ner et al . , ( 1998 ) 12th World AIDS Conference , Geneva , ing to a mammal an effective amount of a vaccine or Switzerland , Jun . 28 - Jul . 3 , 1998 . 
Preferably the other disease - causing organism in swine is immunogenic composition described above . 
selected from the group consisting of : Actinobacillus pleu- 35 The present disclosure likewise relates to nucleotide 
ropneumonia ; Adenovirus ; Alphavirus such as Eastern sequences , characterized in that they are selected from : a ) a 
equine encephalomyelitis viruses ; Bordetella bronchisep nucleotide sequence of SEQ ID NO . 2 ; b ) a nucleotide 
tica ; Brachyspira spp . , preferably B. hyodyentheriae ; B. sequence homologous to a nucleotide sequence such as 
piosicoli , Brucella suis , preferably biovars 1 , 2 , and 3 ; defined in a ) ; c ) a nucleotide sequence complementary to a 
Classical swine fever virus ; Clostridium spp . , preferably Cl . 40 nucleotide sequence such as defined in a ) or b ) , and a 
difficile , Cl . perfringens types A , B , and C , Cl . novyi , nucleotide sequence of their corresponding RNA ; d ) a 
Cisepticum , Cl . tetani ; Coronavirus , preferably Porcine nucleotide sequence capable of hybridizing under stringent 
Respiratory Corona virus ; Eperythrozoonosis suis ; Erysip- conditions with a sequence such as defined in a ) , b ) or c ) ; e ) 
elothrix rhsiopathiae ; Escherichia coli ; Haemophilus para- a nucleotide sequence comprising a sequence such as 
suis , preferably subtypes 1 , 7 and 14 : Hemagglutinating 45 defined in a ) , b ) , c ) or d ) ; and f ) a nucleotide sequence 
encephalomyelitis virus ; Japanese Encephalitis Virus ; Law- modified by a nucleotide sequence such as defined in a ) , b ) , 
sonia intracellularis , Leptospira spp .; preferably Leptospira c ) , d ) or e ) . 
australis ; Leptospira canicola ; Leptospira grippotyphosa ; Nucleotide , polynucleotide or nucleic acid sequence will 
Leptospira icterohaemorrhagicae ; and Leptospira interro- be understood according to the present disclosure as mean 
gans ; Leptospira pomona ; Leptospira tarassovi ; Mycobac- 50 ing both a double - stranded or single - stranded DNA in the 
terium spp . preferably M. avium ; M. intracellulare ; and M. monomeric and dimeric ( so - called in tandem ) forms and the 
bovis ; Mycoplasma hyopneumoniae ( M. hyo ) ; Pasteurella transcription products of said DNAs . 
multocida ; Porcine cytomegalovirus ; Porcine Parvovirus ; Complementary nucleotide sequence of a sequence of the 
Porcine Reproductive and Respiratory Syndrome ( PRRS ) disclosure is understood as meaning any DNA whose 
Virus ; Pseudorabies virus ; Rotavirus ; Salmonella spp .; pref- 55 nucleotides are complementary to those of the sequence of 
erably S. thyhimurium ; and S. choleraesuis ; Staph . hyicus ; the disclosure , and whose orientation is reversed ( antipar 
Staphylococcus spp . preferably Streptococcus spp . , prefer- allel sequence ) .
ably Strep . suis ; Swine herpes virus ; Swine Influenza Virus ; Hybridization under conditions of stringency with a 
Swine pox virus ; Swine pox virus ; Vesicular stomatitis nucleotide sequence according to the disclosure is under 
virus ; Virus of vesicular exanthema of swine ; Leptospira 60 stood as meaning a hybridization under conditions of tem 
Hardjo ; and / or Mycoplasma hyosynoviae . perature and ionic strength chosen in such a way that they 
An “ immunological active component ” as used herein allow the maintenance of the hybridization between two 
means a component that induces or stimulates the immune fragments of complementary DNA . 
response in an animal to which said component is admin- Among the nucleotide sequences according to the disclo 
istered . According to a preferred embodiment , said immune 65 sure , those are likewise preferred which can be used as a 
response is directed to said component or to a microorgan- primer or probe in methods allowing the homologous 
ism comprising said component . According to a further sequences according to the disclosure to be obtained , these 
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methods , such as the polymerase chain reaction ( PCR ) , described by Kievitis et al . in 1991 ; the SDA technique 
nucleic acid cloning and sequencing , being well known to ( Strand Displacement Amplification ) ( Walker et al . , 1992 ) ; 
the person skilled in the art . the TMA technique ( Transcription Mediated Amplification ) . 
Among said nucleotide sequences according to the dis- The polynucleotides of the disclosure can also be 
closure , those are again preferred which can be used as a 5 employed in techniques of amplification or of modification 
primer or probe in methods allowing the presence of IDV or of the nucleic acid serving as a probe , such as : the LCR 
one of its variants such as defined below to be diagnosed . technique ( Ligase Chain Reaction ) , described by Landegren 
Modified nucleotide sequence will be understood as et al . in 1988 and improved by Barany et al . in 1991 , which 
meaning any nucleotide sequence obtained by mutagenesis employs a thermostable ligase ; the RCR technique ( Repair 
according to techniques well known to the person skilled in 10 Chain Reaction ) , described by Segev in 1992 ; the CPR 
the art , and containing modifications with respect to the technique ( Cycling Probe Reaction ) , described by Duck et 
normal sequences according to the disclosure , for example al . in 1990 ; the amplification technique with Q - beta repli 
mutations in the regulatory and / or promoter sequences of case , described by Miele et al . in 1983 and especially 
polypeptide expression , especially leading to a modification improved by Chu et al . in 1986 , Lizardi et al . in 1988 , then 
of the rate of expression of said polypeptide or to a modu- 15 by Burg et al . as well as by Stone et al . in 1996 . 
lation of the replicative cycle . The disclosure likewise relates to a pharmaceutical com 
Modified nucleotide sequence will likewise be understood position comprising a compound selected from the follow 
as meaning any nucleotide sequence coding for a modified ing compounds : a ) a nucleotide sequence according to the 
polypeptide such as defined below . disclosure ; b ) a polypeptide according to the disclosure ; or 
In the present description , the terms polypeptide , peptide 20 c ) a vector transformed according to the disclosure ; possibly 
and protein are interchangeable . in combination with a pharmaceutically acceptable carrier 
In the case of a substitution , one or more consecutive or and , if need be , with one or more adjuvants of the appro 
nonconsecutive amino acids are replaced by " equivalent ” priate immunity . 
amino acids . The expression “ equivalent ” amino acid is The disclosure also relates to an immunogenic and / or 
directed here at designating any amino acid capable of being 25 vaccine composition , characterized in that it comprises a 
substituted by one of the amino acids of the base structure compound selected from the following compounds : a ) a 
without , however , essentially modifying the biological nucleotide sequence according to the disclosure ; b ) a poly 
activities of the corresponding peptides and such that they peptide according to the disclosure ; or c ) a vector according 
will be defined by the following . These equivalent amino to the disclosure . 
acids can be determined either by depending on their struc- 30 The disclosure is likewise directed at a pharmaceutical 
tural homology with the amino acids which they substitute , composition according to the disclosure , for the prevention 
or on results of comparative tests of biological activity or the treatment of an infection by IDV . 
between the different polypeptides , which are capable of It is understood that “ prevention ” as used in the present 
being carried out . By way of example , the possibilities of disclosure , includes the complete prevention of infection by 
substitutions capable of being carried out without resulting 35 a HEF IDV , but also encompasses a reduction in the severity 
in an extensive modification of the biological activity of the of or incidence of clinical signs associated with or caused by 
corresponding modified polypeptides will be mentioned , the IDV infection . Such prevention is also referred to herein as 
replacement , for example , of leucine by valine or isoleucine , a protective effect . 
of aspartic acid by glutamic acid , of glutamine by aspara- The disclosure likewise concerns the use of a composition 
gine , of arginine by lysine etc. , the reverse substitutions 40 according to the disclosure , for the preparation of a medi 
naturally being envisageable under the same conditions . cament intended for the prevention or the treatment of 
The disclosure likewise relates to nucleotide sequences infection by IDV . 
utilizable as a primer or probe , characterized in that said The compositions according to the disclosure will contain 
sequences are selected from the nucleotide sequences an effective quantity of the compounds of the disclosure , that 
according to the disclosure . 45 is to say in sufficient quantity of said compound ( s ) allowing 
The disclosure additionally relates to the use of a nucleo- the desired effect to be obtained . The person skilled in the art 
tide sequence according to the disclosure as a primer or will know how to determine this quantity , as a function , for 
probe for the detection and / or the amplification of nucleic example , of the age and of the weight of the individual to be 
acid sequences . treated , of the state of advancement of the pathology , of the 
The nucleotide sequences according to the disclosure can 50 possible secondary effects and by means of a test of evalu 
thus be used to amplify nucleotide sequences , especially by ation of the effects obtained on a population range , these 
the PCR technique ( polymerase chain reaction ) ( Erlich , tests being known in these fields of application . 
1989 ; Innis et al . , 1990 ; Rolfs et al . , 1991 ; and White et al . , According to the disclosure , said vaccine combinations 
1997 ) . These oligodeoxyribonucleotide or oligoribonucle- will preferably be combined with a pharmaceutically or 
otide primers advantageously have a length of at least 8 55 veterinary acceptable carrier and , if need be , with one or 
nucleotides , preferably of at least 12 nucleotides , and even more adjuvants of the appropriate immunity . 
more preferentially at least 20 nucleotides . Other amplifi- Vaccines and immunogenic compositions according to the 
cation techniques of the target nucleic acid can be advanta- disclosure can likewise be prepared in the form of a com 
geously employed as alternatives to PCR . position containing a vector according to the disclosure , 
The nucleotide sequences of the disclosure , in particular 60 placed under the control of regulation elements allowing its 
the primers according to the disclosure , can likewise be expression in man or animal . Such a vaccine will advanta 
employed in other procedures of amplification of a target geously comprise , apart from the recombinant vector , a 
nucleic acid , such as : the TAS technique ( Transcription- saline solution , for example a sodium chloride solution . 
based Amplification System ) , described by Kwoh et al . in These compounds can be administered by the systemic 
1989 ; the 3SR technique ( Self - Sustained Sequence Repli- 65 route , in particular by the intravenous route , by the intra 
cation ) , described by Guatelli et al . in 1990 ; the NASBA muscular , intradermal or subcutaneous route , or by the oral 
technique ( Nucleic Acid Sequence Based Amplification ) , or nasal route . In some embodiments , the vaccine compo 
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sition comprising plasmids or polypeptides according to the glycol , can be used to increase the solubility of the ingre 
disclosure will be administered by injection or intranasally , dients in the formulation and the stability of the liquid 
through the food , or by nebulization once or several times , preparation . Further additives that can be employed in the 
staggered over time . present vaccine include , but are not limited to , dextrose , 
Their administration modes , dosages and optimum phar- 5 conventional antioxidants and conventional chelating agents 
maceutical forms can be determined according to the criteria such as ethylenediamine tetraacetic acid ( EDTA ) . Parenteral 
generally taken into account in the establishment of a dosage forms must also be sterilized prior to use . 
treatment adapted to an animal such as , for example , the age It should be appreciated that all scientific and technologi 
or the weight , the seriousness of its general condition , the cal terms used herein have the same meaning as commonly 
tolerance to the treatment and the secondary effects noted . 10 understood by those of ordinary skill in the art . 
Preferably , the vaccine of the present disclosure is admin Another aspect of the present disclosure is the preparation 
istered in an amount that is protective or provides a protec- of the combination vaccine ( s ) or immunogenic composi 
tive effect against IDV infection . tions . Such combinations can be between the different 
Another preferred vaccine of the present disclosure uti- vaccine components described herein . For example , a vac 
lizes suitable plasmids for delivering the HEF IDV nucleo- 15 cine of the present disclosure can include both protein 
tide sequence to an animal in need thereof including to cattle portions and DNA portions of HEF IDV , as described herein , 
or pigs . In contrast to the traditional vaccine that uses live or which are administered concurrently or separately . Addi 
killed cell culture propagated whole virus , this disclosure tionally , the combinations can be between the HEF IDV 
provides for the direct inoculation of cattle or pigs with the vaccine components described herein and antigens of other 
plasmid DNA containing the HEF IDV nucleotide sequence . 20 disease - causing organisms , such as those described above . 
The vaccine can be administered in a single dose or in According to a further aspect , the vaccine or immuno 
repeated doses with single doses being preferred . Single genic composition is first dehydrated . If the composition is 
dose vaccines provide protection after a single dose without first lyophilized or dehydrated by other methods , then , prior 
the need for any booster or subsequent dosages . Protection to vaccination , said composition is rehydrated in aqueous 
can include the complete prevention of clinical signs of 25 ( e.g. saline , PBS ( phosphate buffered saline ) ) or non - aque 
infection , or a lessening of the severity , duration , or likeli- ous solutions ( e.g. oil emulsion ( mineral oil , or vegetable / 
hood of the manifestation of one or more clinical signs of metabolizable oil based / single or double emulsion based ) , 
infection . Dosages may range , for example , from about 1 aluminum - based , carbomer based adjuvant ) .
microgram to about 1,000 micrograms / kg of the animal of According to the present disclosure , an effective amount 
the plasmid DNA containing the HEF IDV sequence , pref- 30 of a combination vaccine administered to an animal in need 
erably 100 to 200 micrograms / kg of the animal of the HEF thereof provides effective immunity or a protective effect 
IDV DNA . Methods are known in the art for determining or against microbiological infections caused by IDV and at 
titrating suitable dosages of active antigenic agent to find least one further pathogen . Preferred combinations of anti 
minimal effective dosages based on the weight of the animal , gens for the treatment and prophylaxis of microbiological 
concentration of the antigen and other typical factors . Pref- 35 diseases in cattle and pigs are listed above . 
erably , the HEF IDV DNA is used as a vaccine . 
Desirably , the vaccine is administered to an animal not yet BRIEF DESCRIPTION OF THE DRAWINGS 
exposed to IDV . 
When administered as a liquid , the present vaccine may The following drawings form part of the present specifi 
be prepared in the form of an aqueous solution , syrup , an 40 cation and are included to further demonstrate certain 
elixir , a tincture and the like . Such formulations are known aspects of the present disclosure . The disclosure may be 
in the art and are typically prepared by dissolution of the better understood by reference to one or more of these 
antigen and other typical additives in the appropriate carrier drawings in combination with the detailed description of 
or solvent systems . Suitable carriers or solvents include , but specific embodiments presented herein . 
are not limited to , water , saline , ethanol , ethylene glycol , 45 FIG . 1 is a depiction of the phylogenetic analysis of 
glycerol , etc. Typical additives are , for example , certified ConD - HEF protein ; 
dyes , flavors , sweeteners and antimicrobial preservatives FIG . 2A is a graph illustrating HI antibody responses in 
such as thimerosal ( sodium ethylmercurithiosalicylate ) . peripheral blood induced by ConD - HEF vaccine and evalu 
Such solutions may be stabilized , for example , by addition ated by hemagglutination inhibition ( HI ) assay ; 
of partially hydrolyzed gelatin , sorbitol or cell culture 50 FIG . 2B is a graph illustrating HI antibody responses in 
medium , and may be buffered by conventional methods peripheral blood induced by the second ConD - HEF vaccine 
using reagents known in the art , such as sodium hydrogen group and evaluated by hemagglutination inhibition ( HI ) 
phosphate , sodium dihydrogen phosphate , potassium hydro- assay ; 
gen phosphate , potassium dihydrogen phosphate , a mixture FIG . 2C is a graph illustrating the mean HI antibody titers 
thereof , and the like . 55 of the two vaccine groups at 3 weeks post final vaccination . 
Liquid formulations also may include suspensions and FIG . 2D is a graph illustrating the relative HI titers that 
emulsions that contain suspending or emulsifying agents in were calculated by normalizing D / 660 HI titer to D / OK HI 
combination with other standard co - formulants . These types titer for each individual animal . 
of liquid formulations may be prepared by conventional FIG . 2E provides depictions of the hemagglutinin - es 
methods . Suspensions , for example , may be prepared using 60 terase - fusion protein ( HEFP ) structure of influenza D virus 
a colloid mill . Emulsions , for example , may be prepared ( PDB ID 5e64 ) ; 
using a homogenizer . FIG . 3 is a graph illustrating IDV RNA load in lung 
Parenteral formulations , designed for injection into body tissues quantified using qRT - PCR ; 
fluid systems , require proper isotonicity and pH buffering to FIG . 4A is a photograph illustrating IDV RNA + cells 
the corresponding levels of body fluids . Isotonicity can be 65 ( black silver grains in radioautographs ) in lung tissues 
appropriately adjusted with sodium chloride and other salts detected using in situ hybridization from the area in the left 
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FIG . 4B is a photograph illustrating IDV RNA + cells FIG . 6D is a photograph of immunohistochemically 
( black silver grains in radioautographs ) in lung tissues stained lung epithelial tissue ; 
detected using in situ hybridization ; FIG . 6E is a photograph of immunohistochemically 
FIG . 4C is a photograph illustrating IDV RNA + cells stained lung epithelial tissue ; 
( black silver grains in radioautographs ) in lung tissues 5 FIG . 6F is a photograph of immunohistochemically 
detected using in situ hybridization from the area in the right stained lung epithelial tissue ; 
red box in FIG . 4B ; FIG . 7A is a micrograph of lung epithelial cells that 
FIG . 4D is a photograph illustrating IDV RNA + cells received the IDV D / 660 vaccine and were challenged intra 
( black silver grains in radioautographs ) in lung tissues nasally with IDV D / 660 ; 
detected using in situ hybridization from the area in the left FIG . 7B is a micrograph of lung epithelial cells that 
red box in FIG . 4E ; received the IDV D / 660 vaccine and were challenged intra 
FIG . 4E is a photograph illustrating IDV RNA + cells in nasally with IDV D / 660 ; 
lung tissues detected using in situ hybridization ( black silver FIG . 7C is a micrograph of lung epithelial cells that 
grains in radioautographs ) ; received a sham vaccine and were challenged intranasally 
FIG . 4F is a photograph illustrating IDV RNA + cells with IDV D / 660 ; 
( black silver grains in radioautographs ) in lung tissues FIG . 7D is a micrograph of lung epithelial cells that 
detected using in situ hybridization from the area in the right received a sham vaccine and were challenged intranasally 
red box in FIG . 4E ; with IDV D / 660 ; 
FIG . 4G is a photograph illustrating IDV RNA + cells FIG . ZE is a micrograph of lung epithelial cells that 
( black silver grains in radioautographs ) in lung tissues received a sham vaccine and were challenged intranasally 
detected using in situ hybridization from the area in the left with IDV D / 660 ; 
red box in FIG . 4H ; FIG . 7F is a micrograph of lung epithelial cells that 
FIG . 4H is a photograph illustrating IDV RNA + cells in received a sham vaccine and were challenged intranasally 
lung tissues detected using in situ hybridization ( black silver 25 with IDV D / 660 ; 
grains in radioautographs ) ; FIG . 76 is a micrograph of lung epithelial cells that 
FIG . 41 is a photograph illustrating IDV RNA + cells received the IDV D / OK vaccine and were challenged intra 
( black silver grains in radioautographs ) in lung tissues nasally with IDV DIOK ; 
detected using in situ hybridization from the area in the right FIG . 7H is a micrograph of lung epithelial cells that red box in FIG . 4H ; received the IDV D / OK vaccine and were challenged intra FIG . 4J is a photograph illustrating IDV RNA + cells nasally with IDV DIOK ; ( black silver grains in radioautographs ) in lung tissues FIG . 71 is a micrograph of lung epithelial cells that detected using in situ hybridization from the area in the left 
red box in FIG . 4K ; received a sham vaccine and were challenged intranasally with IDV D / OK ; FIG . 4K is a photograph illustrating IDV RNA + cells in 35 
lung tissues detected using in situ hybridization ( black silver FIG . 7J is a micrograph of lung epithelial cells that 
grains in radioautographs ) ; received a sham vaccine and were challenged intranasally 
FIG . 4L is a photograph illustrating IDV RNA + cells with IDV D / OK ; 
( black silver grains in radioautographs ) in lung tissues FIG . 7K is a micrograph of lung epithelial cells that 
detected using in situ hybridization from the area in the right 40 received a sham vaccine and were challenged intranasally 
red box in FIG . 4K ; with IDV D / OK ; 
FIG . 5A is a photograph illustrating IDV RNA + cells in FIG . 7L is a micrograph of lung epithelial cells that 
nasal turbinate tissue in the control group detected using in received a sham vaccine and were challenged intranasally 
situ hybridization ; with IDV D / OK ; 
FIG . 5B is a magnified photograph of the area in the red 45 
box in FIG . 5A ; DETAILED DESCRIPTION 
FIG . 5C is a photograph illustrating IDV RNA + cells in 
tracheal tissue in the control group detected using in situ The following detailed description and examples set forth 
hybridization ; preferred materials and procedures used in accordance with 
FIG . 5D is a magnified photograph of the area in the red 50 the present disclosure . It is to be understood , however , that 
box in FIG . 5C ; this description and these examples are provided by way of FIG . 5E is a photograph illustrating IDV RNA + cells in illustration only , and nothing therein shall be deemed to be nasal turbinate tissue in the vaccine group detected using in a limitation upon the overall scope of the present disclosure . situ hybridization ; 
FIG . 5F is a magnified photograph of the area in the red 55 tions ( e.g. , temperature , reaction times , etc. ) have been It should be appreciated that when typical reaction condi box in FIG . 5E ; 
FIG . 5G is a photograph illustrating IDV RNA + cells in given , the conditions both above and below the specified 
tracheal tissue in the vaccine group detected using in situ ranges can also be used , though generally less conveniently . 
hybridization ; The examples are conducted at room temperature ( about 23 ° 
FIG . 5H is a magnified photograph of the area in the red 60 C. to about 28 ° C. ) and at atmospheric pressure unless noted 
box of FIG . 5G ; otherwise . All parts and percents referred to herein are on a 
FIG . 6A is a photograph of immunohistochemically weight basis and all temperatures are expressed in degrees 
stained lung epithelial tissue ; centigrade unless otherwise specified . Further unless noted 
FIG . 6B is a photograph of immunohistochemically otherwise , all components of the disclosure are understood 
stained lung epithelial tissue ; 65 to be disclosed to cover " comprising ” , “ consisting essen 
FIG . 6C is a photograph of immunohistochemically tially of ” , and “ consisting of ” claim language as those terms 
stained lung epithelial tissue ; are commonly used in patent claims . 
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Example 1 nose were kept slightly elevated with respect to the rump for 
15 minutes to prevent the inoculum from flowing out of the 
Materials and Methods nostrils . 
Animals and Animal Procedures Body weight and temperature of the guinea pigs were Guinea pig experiments were conducted by following the 5 
protocol approved by the Institutional Animal Care and Use monitored daily for up to 7 days starting from the day of IDV 
Committees ( IACUC ) at UNL . Twenty - four specific - patho challenge but before virus inoculation ( day 0 ) . At 5 and 7 
gen - free ( SPF ) or viral - antibody - free ( VAF ) , and approxi days post challenge , 2 and 4 animals from each group were 
mately 3 - month - old female guinea pigs of the Dunkin euthanized , respectively . Immediately after euthanasia , 
Hartley strain ( Elm Hill Labs , MA , USA ) were used in this 10 blood , nasal turbinate , septum , soft palate , trachea , lung , and 
study . The animals were individually housed and were ear draining lymph node were collected . Half of collected 
tagged after a 1 - week acclimation period . tissues were fixed in 4 % paraformaldehyde ( PFA ) and the 
Consensus DNA Vaccine Design and Preparation remaining half were snap frozen immediately in liquid 
To develop a vaccine that could prevent both lineages of nitrogen . 
IDV infection , a consensus HEF DNA vaccine was 15 IDV Hemagglutination Inhibition ( HI ) Assay 
designed . The HEF amino acid sequences of 19 IDVS 
isolated between 2011 and 2016 were downloaded from Guinea pig sera were treated with receptor - destroying 
GenBank , from which the consensus sequence ( 664 amino enzyme ( RDE ; Denka Seiken , Tokyo , Japan ) before the HI 
acids ) ( SEQ ID NO . 1 ) was calculated using BioEdit ( Ver assay was performed . The RDE treatment was done accord 
sion 7.2.0 ) . Codons of the consensus HEF gene were opti- 20 ing to the manufacturer's protocol and the hemagglutination 
mized for efficient expression in mammalian cells by using inhibition assay was performed using our previously 
an online tool ( JCat found online at jcat.de ) . After codon described method ( 11 ) . The HI assay was performed against 
optimization , the consensus HEF gene ( SEQ ID NO . 2 ) was the two representative IDV lineage viruses ( D / swine / Okla 
synthesized ( GENEWIZ LLC , NJ , USA ) and inserted into homa / 1334 / 2011 ; D / bovine / Oklahoma / 660 / 2013 ) using 1 % 
the pJW4303 expression vector , which was kindly provided 25 turkey red blood cells ( RBCs ) ( Lampire Biological Labo 
by Dr. Shan Lu ( University of Massachusetts Medical ratories , Pipersville , Pa . , USA ) . 
School , Massachusetts , USA ) . The constructed plasmid with Real - Time qRT - PCR the HEF insert was designated as FluD - Vax and the same 
plasmid without the HEF insert was used as vector control . Primers and probe were designed to target a conserved 
FluD - Vax and control plasmid DNA were prepared by using 30 region of the NP gene ( Table 2 ) . A recombinant plasmid , 
an EndoFree Plasmid Giga Kit ( Cat # 12391 , Qiagen , Ger- containing the full - length NP sequence of the IDV strain 
many ) for guinea pig vaccination . D / swine / Oklahoma / 1334 / 2011 ( accession number : 
Experiment Design JQ922306 ) , was serially diluted and used as qRT - PCR 
Guinea pigs were randomly divided into four groups ( 6 standard . Snap - frozen lung tissue was put into 2 ml tube 
per group ) . Animals in vaccine groups ( Vac 1 and Vac 2 ) 35 pre - filled with stainless steel beads ( RNA - WISTO1 , WIS 
were inoculated into tibialis anterior muscle with FluD - Vax BIOMED LLC , CA ) and homogenized for 2 min using a 
( 200 ug / animal ) 4 times at 4 - week intervals , and animals in MiniBeadBeater - 16 ( BioSpec Products , Inc. OK ) . RNA 
the control groups ( Ctr 1 and Ctr 2 ) were inoculated with the from homogenized lung tissues and plasma specimens was 
same quantity of control plasmid DNA in parallel . A detailed extracted using a QIAamp Viral RNA Mini Kit ( Cat # 52906 , 
vaccination schedule is shown in Table 1 . Qiagen , Germany ) . The qRT - PCR reaction was performed in 
TABLE 1 
Guinea pig vaccination schedule 
Group week 1 week 4 week 8 week 12 week 16 
Vac 1 ( n = 6 ) Challenged with 
IDV - D / OK , 3E5 
TCID50 / 300 ul Ctr 1 ( n = 6 ) 
Vac 2 ( n 
ConD HEF , 
200 ug each 
mock , 
200 ug each 
ConD HEF , 
200 ug each 
mock , 
200 ug each 
ConD HEF , 
200 ug each 
mock , 
200 ug each 
ConD HEF , 
200 ug each 
mock , 
200 ug each 
ConD HEF , 
200 ug each 
mock , 
200 ug each 
ConD HEF , 
200 ug each 
mock , 
200 ug each 
ConD HEF , 
200 ug each 
mock , 
200 ug each 
ConD HEF , 
200 ug each 
mock , 
200 ug each 
= 6 ) Challenged with 
IDV - D / 660 , 3E5 
TCID50 / 300 ul Ctr 2 ( n = 6 ) 
55 IDV Challenge and Sample Collection 20 ul containing 1x TaqMan® Fast Virus 1 - Step Master Mix 
To test the protective efficacy of FluD - Vax against two ( Cat # 4444434 , Thermo Fisher Scientific , USA ) , 500 nM of 
lineages of IDV , animals in the Vac 1 and Ctr 1 groups were each primer , 250 nM of probe , and 5 ul total RNA extracted challenged with a IDV DIOK lineage - representative strain 
( D / swine / Oklahoma / 1334 / 2011 , D / OK ) and Vac 2 and Ctr 2 from supernatants of homogenized guinea pig lung tissues . groups were challenged with a D / 660 lineage - representative 60 at 50 ° C. for 5 min , followed by RT inactivation / initial 
strain ( D / bovine / Oklahoma / 660 / 2013 , D / 660 ) ( Table 1 ) . denaturation step at 95 ° C. for 20 s and 45 cycles of 
IDV stocks were prepared as previously reported ( 11 ) and denaturation at 95 ° C. for 3 s and annealing / extension at 60 ° 
diluted in PBS containing 100 units / ml penicillin , 100 ug / ml C. for 30 s . Fluorescence signal was detected after the 
streptomycin , and 0.3 % BSA ( PBS - PS - BA ) . A 300 ul vol- annealing / extension step at each cycle . All PCR assays were 
ume of IDV inoculum containing 3E5 TCIDso was instilled 65 performed on the CFX96 Real - Time PCR System ( Bio - Rad , 
into the nostrils ( 150 ul on each side ) at 30 days post final California , USA ) . The lower limit of detection for this 
immunization . After IDV challenge , the animal head and method was verified to be around 10 copies / reaction . 
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TABLE 2 
Primers and probe for Real - Time PCR 
.ligo Sequence SEQ ID NO . Position 
NP_Forward 5 ' - AAGCGACGTTCCAAGAACTG 3 1542-1561 
NP_Reverse 5 ' - GGGACTGCAACAGAACCATC 4 1716-1697 
NP_probe 5 ' Fam - TGCTCCGGCACCTTGCCTTCC - 3'Tamra 5 1647-1627 
" Numbering is from the sequence of D / swine / .klahoma / 1334 / 2011 PB1 gene , accession 




In Situ Hybridization ( ISH ) antibody titers of two groups at multiple time points were 
IDV in respiratory tract tissues was detected using in situ compared by two - way ANOVA . Data are presented as 
hybridization ( ISH ) with radioactive isotopes of sulfur ( SS ) mean : SD in FIG . 2 and FIG . 3. P < 0.05 was considered as 
labeled negative - sense RNA probes of HEF and nucleopro- statistically significant . 
tein ( NP ) . HEF ( 1071 bp ) and NP ( 1024 bp ) cDNA templates Results 
were amplified from D / OK HEF and NP gene plasmids Phylogenetic and Antigenic Analysis of Consensus IDV 
using PCR with the following primer pairs containing poly- 20 HEF Protein 
sequences : HEF - forward primer - T7 : IDV is similar to ICV in that it uses only one hemagglu 
AACGTGTAATACGACTCACTATAGGG tinin - esterase - fusion glycoprotein ( HEF ) spike for receptor 
AGGGGCTTCGTTGATGTTGT ( SEQ ID No. 6 ) and HEF binding , receptor destruction , and membrane fusion ( 14 ) . 
primer - SP6 : AACTGGATTTAGGTGACAC- The surface HEF thus represents a key protective immuno 
TATAG AAGATCCTTGTTGCTGGCGT ( SEQ ID NO . 7 ) , 25 gen for the development of a preventive vaccine . Two 
NP - forward primer - T7 : AACGTGTAATACGACTCAC- lineages of IDVs are primarily responsible for current IDV 
TATAGGG TGGCAAGCAAAAAGAACGGG ( SEQ ID global infections ( 1 , 3 , 13 ) . Furthermore , these two distinct 
NO . 8 ) , and NP - reverse primer - 5P6 : AACTGGATT- lineages of IDVs can also co - infect the same animals ( 3 , 20 ) . 
TAGGTGACACTATAGA To develop an IDV vaccine that could prevent infection from 
CCTCTTTTCTTGGGCTGGGA ( SEQ ID NO . 9 ) . Negative 30 both lineages of IDV , we designed and constructed an IDV 
sense riboprobes from HEF and NP were generated by in HEF consensus gene ( ConD - HEF ) based vaccine , named as 
vitro run - off transcription with SP6 RNA polymerase and FluD - Vax . Phylogenetic analysis showed that the amino acid 
were used for detection of viral transcripts . Six - micron sequence of ConD - HEF resembles both lineages , but is 
tissue sections were cut and ISH was conducted by follow- closer to the lineage represented by strain D / swine / Okla 
ing our previously published method ( 18 ) . Slides were 35 homa / 1334 / 2011 ( D / OK ) than the lineage represented by 
exposed for 3 days in radioautography and counter - stained strain D / bovine / Oklahoma / 660 / 2013 ( D / 660 ) ( FIG . 1 ) . As 
with hematoxylin and eosin . Tissue sections were digitized shown in FIG . 1 , the phylogenetic relationship of HEF 
using Scanscope and IDV RNA positivity was reviewed by amino acid sequences between consensus vaccine ( ConD 
two investigators independently . The specificity of IDV HEF ) and 19 IDVs isolates was illustrated in a N - J phylog 
riboprobes were confirmed using HIV - 1 riboprobes as a 40 eny plot ( left panel ) and a Highlighter plot ( right panel ) . In 
negative control probe and rhesus lung tissues as negative the phylogeny plot , the consensus HEF was depicted as a 
control tissues . closed red circle , D / swine / Oklahoma / 1334 / 2011 ( D / OK ) as 
Combined Immunohistochemical Staining and ISH an open blue circle and D / bovine / Oklahoma / 660 / 2013 
To determine the cell type of IDV infected cells , a ( D / 660 ) as an open green circle . Bar length represented 
combination of immunohistochemical staining ( IHCS ) and 45 0.005 amino acid substitutions per site . Amino acid poly 
ISH was performed as previously described ( 19 ) . A pan- morphisms in the highlighter plot were indicated by a 
cytokeratin rabbit polyclonal antibody ( MA5-13203 , 1 : 150 , colored mark . The phylogenetic distance ( average substitu 
Invitrogen ) and diaminobenzidine ( DAB ) with the Dako tions per amino acid ) of ConD - HEF to D / OK is 0.5 % and 
Envision and Peroxidase kit was used for IHCS . Stained D / 660 is 2.6 % . The antigenicity of the consensus HEF 
tissue sections were digitized using Scanscope and viral 50 protein expressed by the FluD - Vax was assessed by West 
RNA ISH signal and immunohistochemically stained epi- ern - blotting . Our data showed that both the full - length HEF 
thelial cell signal was viewed in single color channel and and the cleaved HEF1 ( 16 ) could be recognized by rabbit 
combined color channels using Aperio's Spectrum Plus anti - IDV sera . 
analysis program ( version 9.1 ; Aperio ePathology Solu- FluD - Vax elicited robust HI antibody responses against 
tions ) . 55 both D / OK and D / 660 lineages 
In Situ Cell Death Detection by TUNEL Assay As illustrated in Table 1 , the guinea pigs in the vaccine 
To detect apoptotic cell death in lung tissues , terminal and control groups were immunized with FluD - Vax or 
deoxynucleotidyl transferase dUTP nick end labeling control plasmid DNA , respectively , 4 times at 4 - week inter 
( TUNEL ) assay was performed as we previously described vals . Peripheral blood was collected at 3 weeks post each 
( 19 ) . In situ cell death detection AP Kit ( Cat # 11-684 809 60 vaccination for evaluation of HEF - specific neutralizing anti 
910 , Roche ) and AP substrate ( RNAscope® 2.0 HD Detec- bodies against D / OK and D / 660 using hemagglutination 
tion Kit , RED , ACD ) were used to immunochemically detect inhibition ( HI ) assay . The HI antibody titers against both 
TUNEL - positive apoptotic cells as red color signals . The IDVs increased significantly after the second immunizations 
stained tissue sections were digitized using Scanscope . and peaked after the third immunization . The mean titer of 
Statistical Analysis 65 HI antibodies against D / OK was higher than D / 660 after 
Statistical analyses were performed using GraphPad each vaccine immunization ( FIGS . 2A and 2B ) . Control 
Prism 6.0 ( GraphPad Software , California , USA ) . The HI groups did not generate a detectable HI antibody response at 
course ** , 
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any time point ( Data not shown ) . ConD - HEF vaccine RNA ) , indicating IDV from the respiratory tract can spread 
induced robust HI antibody responses against D / OK and into peripheral blood if the IDV virus burden is very high . 
D / 660 in both vaccine groups . However , the mean magni- However , none of any other animals in the vaccine and 
tudes against D / OK were higher than against D / 660 over the control groups had detectable IDV RNA in plasma . To 
of immunization ( * : P < 0.1 , P < 0.01 , 5 confirm qRT - PCR results , we detected viral RNA in respi 
*** : P < 0.001 ) . Interestingly , after the final vaccination , the ratory tract tissues collected from euthanized animals using mean HI antibody titers to D / OK or D / 660 between the two in situ hybridization ( ISH ) . Consistent with the qRT - PCR 
vaccine groups ( Vac 1 and Vac 2 ) were similar ( FIG . 2C ) , results , ISH confirmed that all of the animals in the control indicating that our vaccine induced a similar - level of groups were infected after IDV intranasal challenge , evident immune responses between the Vacl and Vac2 groups . In 10 
addition , we also calculated the relative HI antibody titers of by the presence of abundant IDV VRNA positive cells in 
D / 660 to D / OK and found the mean ratio of D / 660 versus respiratory tract tissues , such as in lung ( FIG . 4 ) and nasal turbinate and tracheal tissues ( FIG . 5 ) . The presence of IDV D / OK HI titers was 0.67 ( FIG . 2D ) . The relative HI titers 
were calculated by normalizing D / 660 HI titer to D / OK HI VRNA positive cells in nasal turbinate , septum , trachea , and 
titer for each individual animal . Error bars represent stan- 15 lung tissues , further confirmed that IDV can infect both the 
dard deviations . upper and lower respiratory tract . Of note , IDV has a 
To generate the pictures in FIG . 2E , the hemagglutinin predisposition to infect the lungs ( FIGS . 4 & 5 ) . As shown 
esterase - fusion protein ( HEFP ) structure of influenza D in the FIGS . 4 & 5 , both lineage representative IDVs 
virus ( PDB ID 5e64 ) was selected as a template , and all infected bronchioles and alveoli of lung tissues with more 
models received QMEAN value -0.45 . The trimer formation 20 VRNA + cells found in bronchioles than alveoli . Represen 
was made refereeing HEFP structure of influenza C virus tative images of FIG . 5 show that no IDV RNA + cells ( black 
( 1fic ) . One subunit was colored in white , while other two silver grains in radioautographs , red arrows ) were detected 
were in light green . Graphics were prepared by the PyMOL in any nasal turbinate ( E & F , animal 1099 ) and tracheal 
Molecular Graphics System , Version 1.8 Schrodinger , LLC tissues ( G & H , animal 1099 ) of animals who received the 
( New York , N.Y. , USA ) . 25 FluD - Vax vaccine and were subsequently challenged with 
Efficacy of FluD - Vax Protection Against IDV Infections IDV D / OK or D / 660 . IDV RNA + cells ( black silver grains 
To evaluate the protective efficacy of consensus FluD - Vax in radioautographs ) were detected in nasal turbinate ( A & B , vaccine against two lineages of IDV infection , the guinea animal 1084 ) and tracheal tissues ( C & D , animal 1099 ) of pigs in the Vac 1 and Ctr 1 groups were challenged with IDV control animals who received the sham vaccine and were D / OK and the Vac 2 and Ctr 2 groups were challenged with 30 subsequently challenged with IDV D / OK or D / 660 . Insets IDV D / 660 . A minimal loss of body weight ( < 5 % on are magnified in images marked by shown arrows . As average ) post viral challenge occurred in all groups with a 
slightly more reduction in body weight observed in the expected , we did not find IDV infected cells in the draining 
vaccine group after D / OK challenge compared to the control lymph node tissues of the lungs . Pan - cytokeratin immuno histochemical staining in combination with ISH confirmed group . The body temperature of animals in both vaccine and 35 
control groups remained stable without significant fluctua that IDV infected cells were epithelial cells ( FIG . 6 ) . In FIG . 
tion FIG . 3 ) . 6 , representative images show epithelial cells in lung tissues 
To measure IDV infection , qRT - PCR and ISH were used that were immunohistochemically stained as brown ( Brown , 
to detect viral RNA in respiratory tract tissues collected from in B , C , E , & F , animal 1084 ) with a pan - cytokeratin 
euthanized animals . Most IDV quantitative real - time PCR 40 antibody and with IDV RNA underlaid of silver grains in 
assays were designed based on the originally isolated PB1 radioautographs as cyan , yellow , or black color ( red arrows ) 
sequence ( 4 ) . Recently , Faccini S and colleagues improved with different channel separation . 
this assay by targeting the primers and probe to the highly IDV Infection Caused Apoptosis in Lung Tissues 
conserved segment of PB1 ( 21 ) . Like PB1 , NP is another To determine whether IDV infection could cause pro 
conserved gene in influenza viruses including IDV , which 45 gramed cell death in lung tissues , we conducted TUNEL 
has been a primary target for RT - PCR assay development . assays on lung tissues from all of the animals in the vaccine 
The new method developed in our study can serve as an and control groups . We detected apoptotic cells in lung 
alternative to the RT - PCR assay targeting the PB1 gene as tissues on days 5 and 7 post IDV D / 660 ( FIG . 7C - F ) and 
published previously . In addition , there were other reasons D / OK ( FIG . 71 - L ) infection in animals from the control 
make us develop the current NP gene based real - time PCR 50 groups . TUNEL - positive cells were mainly localized in the 
method . We did not have the PB1 standard used in the epithelial cells lining alveoli ( FIGS . 7C , E , I & K , black 
aforementioned assay , therefore , we developed a NP gene arrows ) and bronchioles ( FIGS . 7D , F , H & L , black arrows 
based real - time PCR method . High viral loads were readily within blue circles ) . However , TUNEL - positive cells were 
detected using qRT - PCR in all the lung tissues of guinea pigs also detected in non - epithelial cells ( FIG . 7 , green arrows ) . 
from both control groups , immunized with a sham vaccine 55 In contrast , we did not observe TUNEL - positive cells in 
and challenged with either D / OK or D / 660 IDV . The mean animals from the vaccine group ( FIGS . 7A - B & G - H ) . 
viral RNA load in the D / OK control group ( Mean + SD , Discussion 
7.41 + 0.81 , log 10 ) was significantly higher than the D / 660 The newly identified influenza D virus ( DV ) has been 
control group ( 5.52 : 2.52 ) ( FIG . 3 ) . In contrast , no IDV viral demonstrated to infect economically important domestic 
RNA was detected in any lung tissues from the vaccine 60 livestock , such as swine and cattle . IDV infection has been 
groups , immunized with FluD - Vax and challenged with reported to be significantly associated with bovine respira 
either D / OK or D / 660 IDV ( FIG . 3 ) . To investigate whether tory disease complex ( BRDC ) , which is the most economi 
IDV exists in peripheral blood in IDV infected animals , we cally significant disease affecting the U.S. cattle industry . 
conducted qRT - PCR and found that one animal was IDV While the level of infectivity and pathogenicity of IDV to 
positive in plasma ( 4.49E10 copies / ml ) . The animal with 65 humans remains to be determined , IDV has the potential to 
IDV positive plasma was infected with D / OK and had the infect humans . IDV seroprevalence was estimated to be over 
highest viral load in lung tissues ( 8.5E10 copies / ug total 90 % in individuals working closely with cattle . Moreover , 
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IDV has a broad host range , which could enable IDV to gain D / OK and D / 660 intranasal challenge , indicating vaccine 
virulence due to continual mutation , recombination , and elicited immunity is potent enough to protect against both 
evolution . lineages of IDV infection ( FIG . 3-5 ) . In the FIG . 4 figures , 
The development of a protective IDV vaccine is needed . IDV RNA + cells ( black silver grains in radioautographs ) 
However , the development of an effective vaccine is not 5 were detected in all of the lung tissues of animals who 
simple , as a previous study showed that a chemical inacti- received the sham vaccine ( control ) and subsequently chal 
vated IDV vaccine did not provide sterilizing protection lenged intranasally with IDV DIOK ( A - C , animal 1084 ) or 
against even homologous virus challenge in bovine . As D / 660 ( G - I , animal 1091 ) , but were not detected in any lung 
aforementioned , two genetically and serologically distinct tissues of animals who received the FluD - Vax vaccine and 
lineages of IDV have been found to be co - circulating in 10 subsequently challenged with IDV D / OK ( D - F , animal 
cattle and equine . Therefore , This disclosure describes the 1099 ) or D / 660 ( J - L , animal 1106 ) . Red insets in the middle 
development of a vaccine that could prevent infection by panel are magnified and shown in the left and right panels . 
both lineages of IDV . Consensus sequence - based vaccine is In contrast , all animals in the control groups were infected 
a widely used approach to minimize the sequence diversity after IDV challenge . 
between a vaccine strain and circulating viruses , which can 15 After D / OK and D / 660 challenge , infected animals in the 
create an artificial sequence to " centralize ” the immunoge- control groups had higher viral RNA loads in respiratory 
nicity of the vaccine antigen . In addition to the consensus tissues at 5 dpi than 7 dpi by both q - RT - PCR and ISH assays , 
sequence - based vaccine development approach , " ancestor which is consistent with our previous study . IDV RNA cells 
and ' center of the tree ' methods have also been applied to were detected in nasal turbinate , nasal septum , trachea , and 
minimize the distance / mismatch of antigens between a vac- 20 lung tissues , indicating IDV can infect and replicate within 
cine and circulating viruses . As previously reported , when the entire respiratory tract . Notably , within lung tissues , viral 
designing a consensus vaccine from the sequences of a RNA + cells were detected in both alveoli and bronchioles , 
symmetric phylogeny , these three methods generate very but more in bronchiolar cells . Using a combination of IHCS 
similar sequences . However , if the original sequences are and ISH , it was shown that IDV solely infected epithelial 
from an asymmetric phylogeny , the consensus sequence will 25 cells . Although the exact protective mechanisms of the 
have a bias toward the dominant cluster of the input . In this consensus vaccine against prevalent lineages of IDV infec 
study , a DNA vaccine encoding consensus IDV HEF protein tion was not fully investigated in this study , the results 
( ConD - HEF ) was designed and constructed . HEF surface revealed that protection is correlated with HI antibody 
protein was chosen for its key role in receptor binding , responses . One concern during IDV vaccine design is the 
receptor destruction , and membrane fusion . Phylogenetic 30 potential for escape mutations that could minimize protec 
analysis showed that ConD - HEF is close to the center of the tion . However , the DNA vaccine expressing consensus IDV 
IDV phylogenetic tree with a slight bias toward the lineage HEF in this study provided complete protection and pre 
represented by D / OK ( FIG . 1 ) . No further optimization was vented the occurrence of IDV escape mutations . However , 
done to reduce this bias , because in natural infection , D / OK IDV mutations can readily develop during IDV natural 
could generate relatively higher cross - reactive antibodies to 35 infection , thus a broad understanding of potentially mutated 
D / 660 represented lineage than D / 660 to D / OK . In this antigenic sites in IDV vaccine design is important . 
study , 19 full - length IDV HEFs were used for the consensus The data suggested that the consensus HEF may be a good 
vaccine design , including the 10 sequences that were pre- immunogen to protect against different lineages of IDV in 
viously analyzed for the identification of the two major large animals or even in humans . Further investigation is 
circulating lineages ( D / OK and D / 660 ) . For future vaccine 40 warranted to compare its efficacy with other vaccine modali 
design , including additional viral sequences , especially ties , such as inactivated and vectored vaccines . 
sequences that were isolated from different geographic loca- Currently , the pathogenesis and resulting consequences of 
tions , may further optimize the coverage of a consensus IDV infection in economically important animals are largely 
DNA IDV vaccine . unknown . Apoptosis has been demonstrated to be an impor 
A previous study by this team established a guinea 45 tant anti - viral host defense to restrict influenza A and B virus 
pigs / IDV model . With this model humoral immune replication . Paradoxically , apoptosis has also been impli 
responses elicited by the consensus HEF DNA vaccine cated in inducing respiratory tissue damage during influenza 
( FluD - Vax ) were evaluated . HI antibodies in blood against virus infection . It was found for the first time that IDV 
both D / OK and D / 660 IDVs were detectable after the first infection induced TUNEL - positive apoptotic cells in epithe 
immunization , were significantly boosted after the second 50 lial cells lining alveoli ( FIGS . 7C , E , I & K , black arrows ) 
immunization ( > 1:40 ) , and peaked after the third immuni- and bronchioles ( FIGS . 7D , F , H & L , black arrows within 
zation ( FIGS . 2A and 2B ) . In this proof - of - concept study , in blue dotted circles ) in lung tissues of infected animals . 
order to induce optimal humoral responses and achieve Furthermore , we observed TUNEL - positive non - epithelial 
better protection , immunization was done 4 times . However , cells ( FIG . 7 , green arrows ) . Our results demonstrate that 
sterilizing protection may be induced by less than 4 immu- 55 IDV infection causes apoptosis in lung tissues . Nevertheless , 
nizations and future studies are needed to determine the the dichotomy of protective and detrimental roles of apop 
minimal number of immunizations to achieve sterilizing tosis during IDV infection remains to be defined in future 
protection . A more robust HI antibody responses against studies . 
D / OK than against D / 660 ( FIG . 2 ) was observed , which may summary , this study has demonstrated that a DNA 
be due to the intentional phylogenetic bias design of our 60 vaccine expressing consensus IDV HEF can provide com 
consensus vaccine to D / OK . In silico comparative modeling plete protection , which is correlated with HEF - specific anti 
of D / OK , D / 660 and ConD HEF protein structures by body responses in a guinea pig model . Further , this study 
SWISS - MODEL server as performed and found several clearly demonstrated that IDV infects epithelial cells of both 
amino acid substitutions in the receptor binding site of the upper and lower respiratory tract , including alveoli and 
D / 660 HEF ( FIG . 2E ) . Although the consensus DNA vac- 65 bronchioles in lung tissues . More importantly , we found for 
cine elicited various levels of HI antibodies against D / OK the first time that IDV infection can induce programed cell 
and D / 660 , it protected all vaccinated animals from IDV death in lung tissues . 
In 
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SEQUENCE LISTING 
< 160 > NUMBER OF SEQ ID NOS : 9 
< 210 > SEQ ID NO 1 
< 211 > LENGTH : 664 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : consensus sequence of hemagglutinin esterase 
fusion protein of IDV 
< 400 > SEQUENCE : 1 
Met Phe Leu Leu Leu Ala Thr Ile Thr Ala Ile Thr Ala Cys Gin Ala 
1 5 10 15 
Glu Arg Glu Leu Ile Cys Ile Val Gln Arg Val Asn Glu Ser Phe Ser 
20 25 30 
Leu His Ser Gly Phe Gly Gly Asn Val Tyr Ser Met Lys Thr Glu Pro 
40 45 35 
Met Thr Gly Phe Thr Asn Val Thr Lys Gly Ala Ser Val Ile Asn Gln 
50 55 60 
Lys Asp Trp Ile Gly Phe Gly Asp Ser Arg Thr Asp Leu Thr Asn Asp 
65 70 75 80 
Gin Phe Pro Ala Ser Ser Asp Val Pro Leu Ala Val Ala Lys Lys Phe 
85 95 90 
Arg Ser Leu Ser Gly Ala Ser Leu Met Leu Ser Ala Phe Gly Pro Pro 
100 105 110 
Gly Lys Val Asp Tyr Leu Tyr Gin Gly Cys Gly Lys Glu Lys Val Phe 
115 120 125 
Tyr Glu Gly Val Asn Trp Ser Pro Glu Ala Gly Ile Asp Cys Phe Gly 
130 135 140 
Ser Asn Trp Thr Gin Thr Lys Lys Asp Phe Tyr Ser Arg Ile Tyr Glu 
145 150 155 160 
Ala Ala Arg Gly Ser Thr Cys Met Thr Leu Val Asn Ser Leu Asp Thr 
165 170 175 
Lys Ile Ser Ser Thr Thr Ala Thr Ala Gly Thr Ala Ser Ser Cys Ser 
180 185 190 
Ser Ser Trp Met Lys Ser Pro Leu Trp Tyr Ala Glu Ser Ser Val Asn 
195 200 205 
Pro Gly Ala Lys Pro Gin Val Cys Gly Thr Glu Gin Ser Ala Thr Phe 
210 215 220 
Thr Leu Pro Thr Ser Phe Gly Ile Tyr Lys Cys Asn Lys His Val Val 
225 230 235 240 
Gin Leu Cys Tyr Phe Val Tyr Glu Asn Lys Thr Thr Phe Asn Thr Phe 
245 250 255 
Gly Cys Gly Asp Tyr Tyr Gln Asn Tyr Tyr Asp Gly Asn Gly Asn Leu 
260 265 270 
Ile Gly Gly Met Asp Asn Arg Val Ala Ala Tyr Arg Gly Ile Ala Asn 
275 280 285 
Ala Gly Val Lys Ile Glu Cys Pro Ser Lys Ile Leu Asn Pro Gly Thr 
290 295 300 
Tyr Ser Ile Arg Ser Thr Pro Arg Phe Leu Leu Val Pro Lys Arg Ser 
305 310 315 320 
Tyr Cys Phe Asp Thr Asp Gly Gly Tyr Pro Ile Gin Val Val Gin Ser 
325 330 335 
Glu Trp Ser Ala Ser Arg Arg Ser Asp Asn Ala Thr Glu Glu Ala Cys 
340 345 350 
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Leu Gin Thr Glu Gly Cys Ile Phe Ile Lys Lys Thr Thr Pro Tyr Val 
355 360 365 
Gly Glu Ala Asp Asp Asn His Gly Asp Ile Glu Met Arg Gin Leu Leu 
370 375 380 
Ser Gly Leu Gly Asn Asn Asp Thr Val Cys Val Ser Gin Ser Gly Tyr 
385 390 395 400 
Thr Lys Gly Glu Thr Pro Phe Val Lys Asp Tyr Leu Ser Pro Pro Lys 
405 410 415 
Tyr Gly Arg Cys Gin Leu Lys Thr Asp Ser Gly Arg Ile Pro Thr Leu 
420 425 430 
Pro Ser Gly Leu Ile Ile Pro Gin Ala Gly Thr Asp Ser Leu Met Arg 
435 440 445 
Thr Leu Thr Pro Ala Thr Arg Ile Phe Gly Ile Asp Asp Leu Ile Phe 
450 455 460 
Gly Leu Leu Phe Val Gly Phe Val Ala Gly Gly Val Ala Gly Gly Tyr 
465 470 475 480 
Phe Trp Gly Arg Ser Asn Gly Gly Gly Gly Gly Ala Ser Val Ser Ser 
485 490 495 
Thr Gin Ala Gly Phe Asp Lys Ile Gly Lys Asp Ile Gin Gin Leu Arg 
500 505 510 
Asn Asp Thr Asn Ala Ala Ile Glu Gly Phe Asn Gly Arg Ile Ala His 
515 520 525 
Asp Glu Gin Ala Ile Lys Asn Leu Ala Lys Glu Ile Glu Asp Ala Arg 
530 535 540 
Ala Glu Ala Leu Val Gly Glu Leu Gly Ile Ile Arg Ser Leu Ile Val 
545 550 555 560 
Ala Asn Ile Ser Met Asn Leu Lys Glu Ser Leu Tyr Glu Leu Ala Asn 
565 570 575 
Gin Ile Thr Lys Arg Gly Gly Gly Ile Ala Gln Glu Ala Gly Pro Gly 
580 585 590 
Cys Trp Tyr Val Asp Ser Glu Asn Cys Asp Ala Ser Cys Lys Glu Tyr 
595 600 605 
Ile Phe Asn Phe Asn Gly Ser Ala Thr Val Pro Thr Leu Arg Pro Val 
610 615 620 
Asp Thr Lys Val Val Ile Thr Ser Asp Pro Tyr Tyr Leu ly Ser Thr 
625 630 635 640 
Ile Ala Leu Cys Leu Leu Gly Leu Val Ala Ile Ala Ala Ser Val Gly 
645 650 655 
Val Ile Trp Ile Cys Cys Lys Lys 
660 
< 210 > SEQ ID NO 2 
< 211 > LENGTH : 1995 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Consensus nucleotide sequence of hemagglutinin 
esterase fusion protein of IDV 
< 400 > SEQUENCE : 2 
atgttcctgc tgctggccac catcaccgcc atcaccgcct gccaggccga gagggagctg 60 
atctgcatcg tgcagagggt gaacgagagc ttcagcctgc acagcggctt cggcggcaac 120 
gtgtacagca tgaagaccga gcccatgacc ggcttcacca acgtgaccaa gggcgccagc 180 
gtgatcaacc agaaggactg gatcggettc ggcgacagca ggaccgacct gaccaacgac 240 
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cagttccccg ccagcagoga cgtgcccctg gccgtggcca agaagttcag gagcctgage 300 
ggcgccagcc tgatgctgag cgccttcggc ccccccggca aggtggacta cctgtaccag 360 
ggctgcggca aggagaaggt gttctacgag ggcgtgaact ggagccccga ggccggcatc 420 
gactgcttcg gcagcaactg gacccagacc aagaaggact tctacagcag gatctacgag 480 
gccgccaggg gcagcacctg catgaccctg gtgaacagcc tggacaccaa gatcagcago 540 
accaccgcca ccgccggcac cgccagcagc tgcagcagca gctggatgaa gagccccctg 600 
tggtacgccg agagcagcgt gaaccccggc gocaagcccc aggtgtgcgg caccgagcag 660 
agcgccacct tcaccctgcc caccagcttc ggcatctaca agtgcaacaa gcacgtggtg 720 
cagctgtgct acttcgtgta cgagaacaag accaccttca acaccttcgg ctgcggcgac 780 
tactaccaga actactacga cggcaacggc aacctgatog goggcatgga caacagggtg 840 
gccgcctaca ggggcatcgc caacgccggc gtgaagatcg agtgccccag caagatcctg 900 
aaccccggca cctacagcat caggagcacc cccaggttcc tgctggtgcc caagaggagc 960 
tactgcttcg acaccgacgg cggctacccc atccaggtgg tgcagagcga gtggagcgcc 1020 
agcaggagga gcgacaacgc caccgaggag gcctgcctgc agaccgaggg ctgcatcttc 1080 
atcaagaaga ccacccccta cgtgggcgag gccgacgaca accacggcga catcgagatg 1140 
aggcagctgc tgagcggcct gggcaacaac gacaccgtgt gcgtgagcca gagoggctac 1200 
accaagggcg agaccccctt cgtgaaggac tacctgagcc cccccaagta cggcaggtgc 1260 
cagctgaaga ccgacagcgg caggataccc accctgccca gcggcctgat catcccccag 1320 
gccggcaccg acagcctgat gaggaccctg acccccgcca ccaggatott cggcatcgac 1380 
gacctgatct tcggcctgct gttcgtgggc ttcgtggccg goggcgtggc cggcggctac 1440 
ttctggggca ggagcaacgg cggcggcggc ggcgccagcg tgagcagcac ccaggccggc 1500 
ttcgacaaga tcggcaagga catccagcag ctgaggaacg acaccaacgc cgccatcgag 1560 
ggcttcaacg gcaggatcgc ccacgacgag caggccatca agaacctggc caaggagato 1620 
gaggacgcca gggccgaggc cctggtgggc gagctgggca tcatcaggag cctgatcgtg 1680 
gccaacatca gcatgaacct gaaggagagc ctgtacgagc tggccaacca gatcaccaag 1740 
aggggcggcg gcatcgccca ggaggccggc cccggctgct ggtacgtgga cagcgagaac 1800 
tgcgacgcca gctgcaagga gtacatcttc aacttcaacg gcagcgccac cgtgcccacc 1860 
ctgaggcccg tggacaccaa ggtggtgatc accagcgacc cctactacct gggcagcacc 1920 
atcgccctgt gcctgctggg cctggtggcc atcgccgcca gcgtgggcgt gatctggato 1980 
tgctgcaaga agtag 1995 
< 210 > SEQ ID NO 3 
< 211 > LENGTH : 20 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : artificial primer for IDV 
< 400 > SEQUENCE : 3 
aagcgacgtt ccaagaactg 20 
< 210 > SEQ ID NO 4 
< 211 > LENGTH : 20 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : artificial primer for IDV 
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< 400 > SEQUENCE : 4 
gggactgcaa cagaaccato 20 
< 210 > SEQ ID NO 5 
< 211 > LENGTH : 21 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : artificial primer for IDV 
< 400 > SEQUENCE : 5 
tgctccggca ccttgccttc c 21 
< 210 > SEQ ID NO 6 
< 211 > LENGTH : 46 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : artificial primer for IDV 
< 400 > SEQUENCE : 6 
aacgtgtaat acgactcact atagggaggg gcttcgttga tgttgt 46 
< 210 > SEQ ID NO 7 
< 211 > LENGTH : 44 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : artificial primer for IDV 
< 400 > SEQUENCE : 7 
aactggattt aggtgacact atagaagatc cttgttgctg gcgt 44 
< 210 > SEQ ID NO 8 
< 211 > LENGTH : 46 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : artificial primer for IDV 
< 400 > SEQUENCE : 8 
aacgtgtaat acgactcact atagggtggc aagcaaaaag aacggg 46 
< 210 > SEQ ID NO 9 
< 211 > LENGTH : 45 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : artificial primer for IDV 
< 400 > SEQUENCE : 9 
aactggattt aggtgacact atagacctct tttcttgggc tggga 45 
What is claimed is : 4. The immunogenic composition of claim 1 , further 
1. An immunogenic composition comprising a vector comprising a veterinary acceptable carrier .
having an insert comprising a hemagglutinin esterase - fusion 5. An immunogenic composition comprising a recombi 
protein from the D / OK and D / 660 strains of influenza D 60 nant hemagglutinin esterase - fusion ( HEF ) protein from the 
virus ( IDV ) . D / OK and D / 660 strains of IDV . 
2. The immunogenic composition of claim 1 , wherein said 6. The immunogenic composition of claim 5 , wherein said 
insert has a nucleotide sequence having at least 85 % protein is expressed by a nucleotide sequence having at least 
sequence homology with SEQ ID NO . 2 . 85 % sequence homology with SEQ ID NO . 2 . 
3. The immunogenic composition of claim 1 , further 65 7. The immunogenic composition of claim 5 , wherein said 
comprising at least one antigen from a pathogen other than protein has at least 85 % sequence homology with SEQ ID . 
IDV . NO . 1 . 
5 
10 
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8. The immunogenic composition of claim 5 , further immunogenic composition is selected from the group 
comprising at least one antigen from a pathogen other than consisting of the immunogenic composition of claim 1 , 
IDV . the immunogenic composition of claim 5 , the immu 9. The immunogenic composition of claim 5 , further nogenic composition of claim 10 , the immunogenic comprising a veterinary acceptable carrier . composition of claim 12 , and any combination thereof .10. An immunogenic composition comprising a vector 
having an insert comprising a hemagglutinin esterase - fusion 15. The method of claim 14 , wherein said administration 
protein from influenza D virus ( IDV ) , wherein said insert is delivered via injection , intranasally , or orally . 
has a nucleotide sequence having at least 85 % sequence 16. The method of claim 14 , wherein said administration 
homology with SEQ ID NO . 2 . is performed more than one time . 
11. The immunogenic composition of claim 10 , further 17. The method of claim 14 , further comprising the step 
comprising at least one antigen from a pathogen other than of administering an antigen from another pathogen other 
IDV . than IDV . 
12. An immunogenic composition comprising a recom- 18. The method of claim 17 , wherein said antigen from 
binant hemagglutinin esterase - fusion ( FIEF ) protein from another pathogen other than IDV is combined with said influenza D virus ( IDV ) wherein said protein is expressed by immunogenic composition . 
a nucleotide sequence having at least 85 % sequence homol 19. The method of claim 14 , wherein said animal in need ogy with SEQ ID NO . 2 . thereof is selected from the group consisting of cows and 13. The immunogenic composition of claim 12 , further pigs . comprising at least one antigen from a pathogen other than 20. The method of claim 14 , wherein said reducing the IDV . incidence or severity of clinical signs of IDV infection is in 14. A method of reducing the incidence or severity of IDV 
infection in an animal comprising the steps of : comparison to an animal that has not received an adminis 
administering an effective amount of an immunogenic tration of said immunogenic composition . 
composition to an animal in need thereof , wherein said 
15 
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